◆

Subtypes

6

Ornithine Carbamoyltransferase Deficiency

OTC

Most common urea cycle disorder; X-linked inheritance. Ranges from severe neonatal onset in hemizygous males to late-onset symptomatic carrier females.

Carbamoyl Phosphate Synthetase I Deficiency

CPS1

Autosomal recessive. Severe neonatal hyperammonemia phenotype; one of the proximal mitochondrial defects.

Argininosuccinate Synthetase Deficiency

ASS1

Also known as citrullinemia type I. Autosomal recessive. Marked by elevated plasma citrulline.

Argininosuccinate Lyase Deficiency

ASL

Also known as argininosuccinic aciduria. Autosomal recessive. Associated with chronic liver disease and systemic phenotypes beyond hyperammonemia, including nitric oxide deficiency.

Arginase Deficiency

ARG1

Also known as argininemia. Often later onset with progressive spastic diplegia-predominant neurologic disease and hyperargininemia.

N-Acetylglutamate Synthase Deficiency

NAGS

Autosomal recessive. NAGS produces N-acetylglutamate, the obligate allosteric activator of CPS1. Pharmacologically treatable with carglumic acid.

⚙

Pathophysiology

9

Deficient urea cycle enzyme function

This curated group entry focuses on loss of function in core urea-cycle enzymes required for nitrogen disposal.

hepatocyte link

CPS1 link OTC link ASS1 link ASL link ARG1 link NAGS link

catalytic activity link

liver link

Downstream

Impaired hepatic ureagenesis and ammonia accumulation Loss of catalytic enzyme function reduces urea production and permits ammonia accumulation.

Nitric oxide deficiency in ASL deficiency ASL loss impairs systemic nitric oxide production through reduced endogenous arginine synthesis and impaired use of extracellular arginine.

Hepatic glutathione dysregulation in ASL deficiency ASL deficiency produces a subtype-specific hepatic redox branch with glutathione depletion and altered cysteine utilization.

Arginine and guanidino compound neurotoxicity in ARG1 deficiency ARG1 loss creates the distal urea-cycle branch dominated by hyperargininemia and progressive spastic neurologic disease.

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"Congenital defects of the enzymes or transporters of the urea cycle cause the disease."

Directly supports primary upstream molecular defects in urea-cycle enzymes; transporter defects are outside this entry's current subtype scope.

Impaired hepatic ureagenesis and ammonia accumulation

The urea cycle is the main pathway for ammonia detoxification, localized to periportal hepatocytes. Reduced conversion of ammonia to urea causes accumulation of circulating ammonia and nitrogenous intermediates. Proximal mitochondrial defects (CPS1, OTC, NAGS) produce hyperammonemia with low citrulline and arginine, while distal cytosolic defects (ASS1, ASL, ARG1) cause accumulation of pathway intermediates with variable hyperammonemia.

hepatocyte link

urea cycle link

liver link

Downstream

Hyperammonemic neurotoxicity and cerebral edema Ammonia excess drives astrocyte glutamine loading, edema, and encephalopathic brain injury.

Catabolic nitrogen stress exceeding residual ureagenesis Catabolic illness, fasting, surgery, or protein loading can overwhelm residual urea-cycle flux and precipitate acute decompensation.

Carbamoyl phosphate overflow to pyrimidine pathway In proximal defects, excess carbamoyl phosphate is diverted toward pyrimidine synthesis and orotate production.

Hyperammonemia Failed hepatic nitrogen disposal manifests clinically as hyperammonemia.

Plasma ammonia Reduced ammonia-to-urea conversion raises circulating ammonia.

Plasma glutamine Excess nitrogen is shunted into glutamine, producing hyperglutaminemia.

Plasma citrulline The position of the enzymatic block produces subtype-specific citrulline abnormalities, low in proximal defects and high in ASS1 deficiency.

Argininosuccinic acid ASL deficiency blocks argininosuccinate cleavage and causes argininosuccinic acid accumulation.

Chronic UCD liver disease UCDs can develop chronic liver disease through incompletely resolved mechanisms downstream of the inherited urea-cycle defect.

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"The urea cycle is a metabolic pathway for the disposal of excess nitrogen, which arises primarily as ammonia."

Directly supports the urea cycle as the principal ammonia detoxification pathway.

Catabolic nitrogen stress exceeding residual ureagenesis

Catabolic stressors such as infection, fasting, surgery, childbirth, or high protein intake increase endogenous protein breakdown and nitrogen load. In patients with partial residual urea-cycle function, this excess nitrogen can exceed detoxification capacity and precipitate acute hyperammonemic crises.

protein catabolic process link

liver link

Downstream

Hyperammonemia Excess nitrogen production during catabolism precipitates acute ammonia elevation when residual ureagenesis is insufficient.

Vomiting Acute decompensation in late-onset UCDs commonly includes nausea and vomiting.

Respiratory alkalosis Hyperammonemic decompensation can present with hyperventilation and respiratory alkalosis.

Show evidence (1 reference)

PMID:33409766 SUPPORT Human Clinical

"During metabolic stress induced by infection, childbirth or surgery, a catabolic phase leads to the metabolism of a large amount of proteins. This excess intake will exceed the capacity of the urea cycle, especially if it has an enzymatic deficit. A significant production of ammonia then follows."

Adult UCD review links catabolic stress with excess protein breakdown, exceeded urea-cycle capacity, and ammonia production.

Hyperammonemic neurotoxicity and cerebral edema

Ammonia diffuses freely across the blood-brain barrier and is detoxified primarily in astrocytes by conversion to glutamine via glutamine synthetase. During hyperammonemic crises, glutamine becomes an osmolyte that drives astrocytic swelling and cytotoxic cerebral edema. This is accompanied by disrupted glutamate-glutamine cycling, excitotoxicity, impaired energy metabolism, and altered aquaporin-4 expression, culminating in encephalopathy and seizure susceptibility.

astrocyte link

glutamine biosynthetic process link cellular response to osmotic stress link

brain link

Downstream

Cerebral edema Astrocyte glutamine accumulation acts as an osmolyte and increases brain volume.

Encephalopathy Ammonia-mediated neurotransmission toxicity and astrocyte swelling produce metabolic encephalopathy.

Lethargy Altered alertness is an early neurologic manifestation of ammonia toxicity.

Seizures Ammonia and glutamine elevations increase seizure risk during hyperammonemic crises.

Coma Severe intracranial hypertension and metabolic encephalopathy can progress to coma and death.

Intellectual disability Survivors of neonatal or recurrent hyperammonemic injury can develop long-term cognitive impairment.

Global developmental delay Recurrent or neonatal ammonia-mediated brain injury impairs neurodevelopment.

Abnormality of movement Hyperammonemia and toxic metabolite accumulation can produce increased neuromuscular tone, spasticity, and clonus.

Show evidence (2 references)

PMID:31110235 SUPPORT Human Clinical

"The strategy for therapy is to prevent the irreversible toxicity of high-ammonia exposure to the brain."

Supports ammonia-mediated brain toxicity as a central downstream mechanism.

PMID:33409766 SUPPORT Human Clinical

"Ammonia passes into the circulation and crosses the blood–brain barrier. The ammonia will exert a direct toxic effect on the neurotransmission responsible for part of the neurological symptomatology."

Supports CNS ammonia toxicity as a direct neurologic mechanism in UCD crises.

Carbamoyl phosphate overflow to pyrimidine pathway

In proximal urea cycle defects, particularly OTC deficiency, carbamoyl phosphate accumulates in the mitochondrial matrix and is diverted into the cytosolic pyrimidine synthesis pathway, leading to elevated urinary orotic acid. This overflow is diagnostically useful for distinguishing OTC deficiency from CPS1 deficiency.

pyrimidine nucleotide biosynthetic process link

mitochondrial matrix link

Downstream

Urinary orotic acid Proximal carbamoyl phosphate excess is diverted to pyrimidine synthesis and appears diagnostically as elevated urinary orotic acid, especially in OTC deficiency.

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"two of which, carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial matrix"

Supports the mitochondrial localization of proximal urea cycle enzymes where carbamoyl phosphate accumulates.

Chronic UCD liver disease

Children and adults with UCDs can develop chronic liver disease even outside acute hyperammonemic episodes. Reported manifestations include abnormal liver enzymes, hepatomegaly, abnormal liver ultrasound, steatosis, fibrosis, cirrhosis with portal hypertension, impaired liver function, and liver failure requiring transplantation.

hepatocyte link

liver link

Downstream

Hepatomegaly Hepatomegaly is one reported manifestation within the chronic liver disease spectrum of UCDs.

Show evidence (1 reference)

PMID:33846069 SUPPORT Human Clinical

"Increasingly, studies have demonstrated that children and adults with UCDs are also at risk for developing various forms of chronic liver disease"

Human UCD cohort review supports chronic liver disease as a recognized complication across UCDs.

Hepatic glutathione dysregulation in ASL deficiency

In argininosuccinic aciduria (ASL deficiency), glutathione biosynthesis is dysregulated with upregulated cysteine metabolism but depleted glutathione and downregulated antioxidant pathways. This redox defect provides a molecular basis for chronic liver disease manifestations in ASL deficiency beyond episodic hyperammonemia, and represents a target for mRNA therapy approaches.

hepatocyte link

ASL link

glutathione metabolic process link

liver link

Downstream

Chronic UCD liver disease ASL-associated glutathione depletion and antioxidant-pathway dysregulation contribute to the chronic liver-disease branch of argininosuccinic aciduria.

Show evidence (2 references)

PMID:38198573 SUPPORT Human Clinical

"Here, we describe the dysregulation of glutathione biosynthesis and upstream cysteine utilization in ASL-deficient patients and mice"

The abstract explicitly includes ASL-deficient patients in the glutathione/cysteine dysregulation finding.

PMID:38198573 SUPPORT Model Organism

"Human hASL mRNA encapsulated in lipid nanoparticles improved glutathione metabolism and chronic liver disease."

Supports the preclinical mRNA-therapy component of this ASL-specific hepatic redox mechanism.

Nitric oxide deficiency in ASL deficiency

ASL participates in the citrulline-argininosuccinate-arginine recycling pathway that channels arginine to nitric oxide synthase. ASL deficiency impairs endogenous nitric oxide production, contributing to systemic vascular and neurological phenotypes that are independent of hyperammonemia, including hypertension and neurocognitive deficits.

ASL link

nitric oxide biosynthetic process link

Downstream

Abnormality of movement NO-mediated central catecholamine dysregulation is associated with the late-onset movement-disorder phenotype in ASA.

Global developmental delay Developmental delay occurs within the ASA neurological phenotype associated with NO-mediated central catecholamine dysregulation.

Seizures Epilepsy occurs within the ASA neurological phenotype associated with NO-mediated central catecholamine dysregulation.

Show evidence (2 references)

PMID:22081021 SUPPORT Human Clinical

"Loss of Asl in both humans and mice leads to reduced NO synthesis, owing to both decreased endogenous arginine synthesis and an impaired ability to use extracellular arginine for NO production."

The abstract directly supports reduced nitric oxide synthesis in humans with ASL deficiency.

PMID:37490345 SUPPORT In Vitro

"Previously, we have shown that argininosuccinate lyase deficiency (ASLD) is a novel model system to investigate cell-autonomous, nitric oxide synthase-dependent NO deficiency."

Supports a cell-autonomous nitric oxide deficiency mechanism in ASL-deficient systems.

Arginine and guanidino compound neurotoxicity in ARG1 deficiency

ARG1 deficiency is a distal urea-cycle defect in which chronic hyperargininemia and related guanidino compound accumulation, rather than recurrent severe hyperammonemia alone, dominate the progressive neurologic phenotype. This subtype-specific toxic-metabolite mechanism explains spastic paraplegia-predominant disease.

ARG1 link

L-arginine catabolic process link

brain link

Downstream

Plasma arginine Loss of ARG1-mediated arginine hydrolysis produces persistent hyperargininemia.

Spastic paraplegia Chronic arginine-related neurotoxicity underlies progressive spastic paraparesis.

Show evidence (1 reference)

PMID:26467175 SUPPORT Human Clinical

"ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders."

Review of clinical reports supports hyperargininemia with progressive spastic paraparesis as the ARG1-specific neurologic mechanism.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

14

Digestive 2

Vomiting FREQUENT Vomiting (HP:0002013)

Vomiting is a common decompensation symptom in UCDs; a direct vomiting-specific quote was not available in the currently curated abstracts.

Hepatomegaly OCCASIONAL Hepatomegaly (HP:0002240)

Show evidence (1 reference)

PMID:33846069 SUPPORT Human Clinical

"The manifestations of chronic liver disease in UCDs are variable and may include elevated serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), hepatomegaly, abnormal grey-scale ultrasound pattern of the liver parenchyma, hepatic steatosis, hepatic fibrosis, cirrhosis..."

Supports hepatomegaly as a reported manifestation within the chronic liver disease spectrum of UCDs.

Metabolism 3

Hyperammonemia VERY_FREQUENT Hyperammonemia (HP:0001987)

Show evidence (2 references)

PMID:31110235 SUPPORT Human Clinical

"The urea cycle disorders (UCDs) comprise diseases presenting with hyperammonemia that arise in either the neonatal period (about 50% of cases) or later."

Confirms hyperammonemia as the defining clinical presentation across UCDs.

PMID:30982989 SUPPORT Human Clinical

"UCDs cause hyperammonemia of neonatal (~50%) or late onset that can lead to intellectual disability or death"

Supports hyperammonemia as the core feature with variable age of onset.

Cerebral edema FREQUENT Cerebral edema (HP:0002181)

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"The strategy for therapy is to prevent the irreversible toxicity of high-ammonia exposure to the brain."

Supports brain injury risk from ammonia exposure; cerebral edema is a key mechanism.

Respiratory alkalosis OCCASIONAL Respiratory alkalosis (HP:0001950)

Respiratory alkalosis is a recognized early hyperammonemia sign, but a direct quote was not available in the currently cited abstracts.

Musculoskeletal 1

Spastic paraplegia OCCASIONAL Spastic paraplegia (HP:0001258)

Predominantly associated with arginase deficiency (ARG1). Progressive spasticity is often the presenting feature rather than hyperammonemic crises.

Nervous System 7

Encephalopathy FREQUENT Encephalopathy (HP:0001298)

Show evidence (2 references)

PMID:37938118 SUPPORT Human Clinical

"Hyperammonemia, particularly if severe, causes time- and concentration-dependent neurologic injury."

Supports severity-dependent encephalopathy from hyperammonemia.

PMID:30982989 SUPPORT Human Clinical

"UCDs cause hyperammonemia of neonatal (~50%) or late onset that can lead to intellectual disability or death"

Supports severe neurologic consequences from hyperammonemic episodes.

Seizures FREQUENT Seizure (HP:0001250)

Show evidence (1 reference)

PMID:39121557 SUPPORT Human Clinical

"Seizures are observed in 13% of HA events. Among all HA events with concomitant EEG, subclinical seizures were identified in 27% of crises of encephalopathy without clinical seizures and 53% of crises with clinical seizures."

Quantifies seizure prevalence during UCD crises with EEG monitoring data.

Intellectual disability FREQUENT Intellectual disability (HP:0001249)

Show evidence (1 reference)

PMID:30982989 SUPPORT Human Clinical

"UCDs cause hyperammonemia of neonatal (~50%) or late onset that can lead to intellectual disability or death"

Directly supports intellectual disability as a major outcome of UCDs.

Lethargy FREQUENT Lethargy (HP:0001254)

Show evidence (1 reference)

PMID:37938118 SUPPORT Human Clinical

"Hyperammonemia, particularly if severe, causes time- and concentration-dependent neurologic injury."

Lethargy and altered mental status are dose-dependent neurologic manifestations.

Coma OCCASIONAL Coma (HP:0001259)

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"excessive ammonia leads to life-threatening conditions"

Supports life-threatening neurological deterioration from hyperammonemia.

Global developmental delay FREQUENT Global developmental delay (HP:0001263)

Show evidence (1 reference)

PMID:30982989 SUPPORT Human Clinical

"UCDs cause hyperammonemia of neonatal (~50%) or late onset that can lead to intellectual disability or death"

Supports neurodevelopmental morbidity as a major UCD complication.

Abnormality of movement OCCASIONAL Abnormality of movement (HP:0100022)

Show evidence (1 reference)

PMID:20301631 SUPPORT Human Clinical

"Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death."

GeneReviews directly supports neuromuscular tone abnormalities, spasticity, and ankle clonus as downstream consequences of hyperammonemia and toxic metabolite accumulation.

Growth 1

Failure to thrive FREQUENT Failure to thrive (HP:0001508)

Failure to thrive is common in chronically affected patients, but no growth-specific quote was available in the currently cited abstracts.

🧬

Genetic Associations

6

Ornithine transcarbamylase (OTC) deficiency

X-linked inheritance

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"ornithine transcarbamylase are present in the mitochondrial matrix"

Confirms OTC localization and its role in the urea cycle.

Carbamoyl phosphate synthetase I (CPS1) deficiency

Autosomal recessive

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial matrix"

Directly identifies CPS1 as a mitochondrial urea cycle enzyme.

Argininosuccinate synthetase (ASS1) deficiency

Autosomal recessive

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"argininosuccinate synthetase, argininosuccinate lyase and arginase 1) are present in the cytoplasm"

Directly identifies ASS1 as a cytosolic urea cycle enzyme.

Argininosuccinate lyase (ASL) deficiency

Autosomal recessive

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"argininosuccinate synthetase, argininosuccinate lyase and arginase 1) are present in the cytoplasm"

Directly identifies ASL as a cytosolic urea cycle enzyme.

Arginase 1 (ARG1) deficiency

Autosomal recessive

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"arginase 1) are present in the cytoplasm"

Identifies ARG1 as a cytosolic urea cycle enzyme.

N-Acetylglutamate synthase (NAGS) deficiency

Autosomal recessive

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"N-acetylglutamate synthase and at least two transporter proteins are essential to urea cycle function."

Directly identifies NAGS as essential for urea cycle function.

💊

Treatments

7

Protein-restricted diet

Action: dietary intervention MAXO:0000088

Controlled protein intake to reduce nitrogen load while preserving growth is the cornerstone of chronic UCD management. Natural protein is limited and supplemented with essential amino acid mixtures to maintain adequate nutrition and growth.

Mechanism Target:

MODULATES Catabolic nitrogen stress exceeding residual ureagenesis — Controlled protein intake reduces nitrogen substrate load while preserving enough protein for growth.

Show evidence (1 reference)

PMID:11148548 SUPPORT Human Clinical

"The protein intake should be adjusted to take account of the inborn error and its severity and the patient's age, growth rate, and individual preferences."

Supports dietary titration to the biochemical defect and growth needs.

Target Phenotypes: Hyperammonemia ↗ Failure to thrive ↗

Show evidence (1 reference)

PMID:11148548 SUPPORT Human Clinical

"Diet is one of the mainstays of the treatment of patients with urea cycle disorders."

Directly supports protein-restricted diet as core UCD management.

Nitrogen scavenger therapy

Action: nitrogen scavenger therapy Ontology label: Pharmacotherapy NCIT:C15986

Sodium phenylbutyrate is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine, providing an alternative renal route for waste nitrogen excretion. Glycerol phenylbutyrate is a newer palatable formulation. Sodium benzoate conjugates with glycine to form hippurate for renal excretion.

Mechanism Target:

BYPASSES Impaired hepatic ureagenesis and ammonia accumulation — Benzoate and phenylacetate/phenylbutyrate create alternative renal nitrogen-excretion routes that bypass the blocked urea cycle.

Show evidence (1 reference)

PMID:33409766 SUPPORT Human Clinical

"Alternative pathways to reduce ammonia production and accelerate elimination. Ammonia is diverted to the glycine and hippuric acid pathway by benzoate, and to the glutamine and phenylacetylglutamine pathway allowing elimination in the urine without passing through the urea cycle"

Supports the bypass mechanism of nitrogen scavenger therapy.

Target Phenotypes: Hyperammonemia ↗ Encephalopathy ↗

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"We review here the current concepts of the pathogenesis, diagnostics, including genetics and treatment of UCDs."

Supports nitrogen scavenger therapy as part of standard UCD treatment.

Arginine and citrulline supplementation

Action: nutritional supplementation MAXO:0000106

Arginine supplementation replaces the amino acid that cannot be synthesized endogenously in most UCDs (except ARG1 deficiency). Citrulline supplementation may be preferable as it bypasses intestinal and hepatic first-pass metabolism and has been associated with lower mean ammonia concentrations compared to arginine alone.

Mechanism Target:

MODULATES Impaired hepatic ureagenesis and ammonia accumulation — Arginine and citrulline supplementation replenish downstream urea-cycle intermediates and support residual nitrogen flux, except in ARG1 deficiency where arginine is contraindicated.

Show evidence (1 reference)

PMID:10869432 SUPPORT Human Clinical

"Urea synthesis is altered by alternative route medications and arginine supplementation to the degree that is to be expected from theory."

Human isotope study supports arginine supplementation as a measurable modifier of urea synthesis.

Target Phenotypes: Hyperammonemia ↗

Show evidence (1 reference)

PMID:11148548 SUPPORT Human Clinical

"Most patients, except those with arginase deficiency, will need supplements of arginine"

Supports arginine supplementation as standard for most UCDs while excluding ARG1 deficiency.

Carglumic acid

Action: Pharmacotherapy NCIT:C15986

Carglumic acid (Carbaglu) is a synthetic analog of N-acetylglutamate that directly activates CPS1. It is specifically indicated for NAGS deficiency and is also used for hyperammonemia in organic acidemias. It provides pharmacological bypass of the NAGS enzyme deficiency.

Mechanism Target:

ACTIVATES Impaired hepatic ureagenesis and ammonia accumulation — Carglumic acid replaces the missing N-acetylglutamate signal and activates CPS1-dependent ureagenesis in NAGS deficiency.

Show evidence (1 reference)

PMID:33409766 SUPPORT Human Clinical

"N-Carbamoyl-l-glutamic acid (NCG or Carbaglu®) is a structural analogue of N-acetyl glutamate (NAG) that restores urea cycle function in inherited NAGS and CPS1 deficiency"

Supports carglumic acid as a NAG analog that restores/activates urea-cycle function in NAGS/CPS1 deficiency contexts.

Target Phenotypes: Hyperammonemia ↗

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"N-acetylglutamate synthase and at least two transporter proteins are essential to urea cycle function."

NAGS produces the obligate CPS1 activator; carglumic acid replaces this function.

Acute hyperammonemia management

Action: supportive care MAXO:0000950

Emergency management includes cessation of protein intake, high-calorie glucose infusion to reverse catabolism, intravenous nitrogen scavengers (sodium benzoate, sodium phenylacetate), and arginine supplementation. When ammonia exceeds 500 umol/L or encephalopathy is present, extracorporeal clearance with continuous renal replacement therapy (CRRT) is recommended.

Mechanism Target:

MODULATES Hyperammonemic neurotoxicity and cerebral edema — Acute management lowers ammonia production and increases endogenous or extracorporeal ammonia clearance to prevent irreversible brain injury.

Show evidence (1 reference)

PMID:37938118 SUPPORT Human Clinical

"Management of UCDs emphasizes decreasing ongoing ammonia production, avoiding catabolism, and supporting endogenous and exogenous ammonia clearance."

Supports the multi-pronged acute ammonia-lowering strategy.

Target Phenotypes: Hyperammonemia ↗ Encephalopathy ↗ Cerebral edema ↗ Seizure ↗ Coma ↗

Show evidence (1 reference)

PMID:31110235 SUPPORT Human Clinical

"The strategy for therapy is to prevent the irreversible toxicity of high-ammonia exposure to the brain."

Supports urgent ammonia-lowering treatment during crises.

Liver transplantation

Action: organ transplantation MAXO:0010039

Liver transplantation remains the only curative option for severe UCDs, restoring full urea cycle capacity. It is indicated for patients with recurrent severe hyperammonemic crises despite maximal medical therapy. Benefits include elimination of hyperammonemia risk, dietary liberalization, and improved quality of life, but carry lifelong immunosuppression requirements.

Mechanism Target:

RESTORES Deficient urea cycle enzyme function — Orthotopic liver transplantation replaces deficient hepatic urea-cycle enzyme activity at the organ level.

Show evidence (1 reference)

PMID:11148551 SUPPORT Human Clinical

"Long-term correction of urea cycle disorders is achieved by correction of the enzymatic defect in hepatocytes."

Supports transplantation as correction of the hepatic enzymatic defect.

RESTORES Impaired hepatic ureagenesis and ammonia accumulation — Transplanted liver restores hepatic ureagenesis capacity and reduces recurrent hyperammonemia risk.

Target Phenotypes: Hyperammonemia ↗ Encephalopathy ↗

Show evidence (1 reference)

PMID:11148551 SUPPORT Human Clinical

"Currently, orthotopic liver transplantation is the primary means of achieving this correction."

Directly supports liver transplantation as a long-term corrective therapy for severe UCDs.

Newborn screening

Action: disease screening MAXO:0000124

Some UCDs are detectable through expanded newborn screening by tandem mass spectrometry. Citrullinemia type I (elevated citrulline) and ASL deficiency (elevated argininosuccinic acid) are most reliably detected. Early identification enables pre-symptomatic treatment initiation and prevention of neonatal crises.

Target Phenotypes: Hyperammonemia ↗ Intellectual disability ↗ Global developmental delay ↗

Show evidence (1 reference)

PMID:30982989 SUPPORT Human Clinical

"experience on newborn screening for some UCDs has widened"

Confirms expanding newborn screening programs for UCD detection.

🔬

Biochemical Markers

6

Plasma ammonia (INCREASED)

Context: Elevated plasma ammonia is the cardinal biochemical finding in UCDs. In neonates, levels >200 umol/L suggest IEM; post-neonatal, >100 umol/L is concerning. Very poor prognosis is associated with levels >1000 umol/L.

Show evidence (1 reference)

PMID:37938118 SUPPORT Human Clinical

"Urea cycle disorders (UCDs) cause elevations in ammonia which, when severe, cause irreversible neurologic injury."

Confirms ammonia elevation as the core biochemical abnormality causing injury.

Plasma glutamine (INCREASED)

Context: Glutamine rises as an alternative nitrogen sink when ureagenesis is impaired. In brain, glutamine accumulation in astrocytes drives osmotic swelling and cerebral edema. Each 100 umol/L increase in plasma glutamine increases seizure odds by 1.14-fold during crises.

Show evidence (1 reference)

PMID:39121557 SUPPORT Human Clinical

"1.14 (95% CI, 1.04 to 1.25) times for every 100 μmol/L increase in glutamine"

Quantifies glutamine as a seizure risk biomarker during hyperammonemic crises.

Plasma citrulline (DECREASED)

Context: Low plasma citrulline is characteristic of proximal urea cycle defects (CPS1 and OTC deficiency), reflecting impaired mitochondrial citrulline production. In contrast, citrulline is markedly elevated in ASS1 deficiency (citrullinemia type I).

Urinary orotic acid (INCREASED)

Context: Elevated urinary orotic acid is a key diagnostic biomarker for OTC deficiency, resulting from diversion of accumulated mitochondrial carbamoyl phosphate into the cytosolic pyrimidine synthesis pathway. This finding distinguishes OTC deficiency from CPS1 deficiency.

Plasma arginine (DECREASED)

Context: Arginine is typically low in most UCDs due to impaired urea cycle flux, requiring supplementation. In arginase deficiency (ARG1), arginine is markedly elevated due to failure of the terminal hydrolysis step.

Argininosuccinic acid (INCREASED)

Context: Elevated plasma and urinary argininosuccinic acid is the pathognomonic biomarker for ASL deficiency (argininosuccinic aciduria). It may be detected on newborn screening.

{ }

Source YAML

click to show

name: Urea Cycle Disorder
category: Mendelian
creation_date: '2026-02-16T23:59:29Z'
updated_date: '2026-05-08T22:59:02Z'
synonyms:
- Urea cycle disorders
- UCD
- Urea cycle defect
- Inborn error of ureagenesis
description: 'Urea cycle disorders (UCDs) are a group of inborn errors of metabolism caused by deficiency of one of the six enzymes involved in hepatic urea-cycle function, the principal pathway for disposal of waste nitrogen. Impaired conversion of ammonia to urea leads to recurrent or persistent hyperammonemia, particularly during periods of catabolic stress, with risk of acute encephalopathy, cerebral edema, seizures, and long-term neurologic injury. The estimated incidence is approximately 1 in 35,000 births. Severity and age of onset depend on residual enzyme function and are related to the respective gene mutations. Classical presentations range from neonatal-onset rapidly progressive encephalopathy to late-onset episodic hyperammonemia triggered by illness or protein loading.

  '
disease_term:
  preferred_term: urea cycle disorder
  term:
    id: MONDO:0004739
    label: urea cycle disorder
parents:
- Metabolic Disease
- Inborn Error of Metabolism
prevalence:
- notes: Estimated combined incidence of approximately 1 in 35,000 births in North America.
has_subtypes:
- name: Ornithine Carbamoyltransferase Deficiency
  description: 'Most common urea cycle disorder; X-linked inheritance. Ranges from severe neonatal onset in hemizygous males to late-onset symptomatic carrier females.

    '
  genes:
  - preferred_term: OTC
- name: Carbamoyl Phosphate Synthetase I Deficiency
  description: 'Autosomal recessive. Severe neonatal hyperammonemia phenotype; one of the proximal mitochondrial defects.

    '
  genes:
  - preferred_term: CPS1
- name: Argininosuccinate Synthetase Deficiency
  description: 'Also known as citrullinemia type I. Autosomal recessive. Marked by elevated plasma citrulline.

    '
  genes:
  - preferred_term: ASS1
- name: Argininosuccinate Lyase Deficiency
  description: 'Also known as argininosuccinic aciduria. Autosomal recessive. Associated with chronic liver disease and systemic phenotypes beyond hyperammonemia, including nitric oxide deficiency.

    '
  genes:
  - preferred_term: ASL
- name: Arginase Deficiency
  description: 'Also known as argininemia. Often later onset with progressive spastic diplegia-predominant neurologic disease and hyperargininemia.

    '
  genes:
  - preferred_term: ARG1
- name: N-Acetylglutamate Synthase Deficiency
  description: 'Autosomal recessive. NAGS produces N-acetylglutamate, the obligate allosteric activator of CPS1. Pharmacologically treatable with carglumic acid.

    '
  genes:
  - preferred_term: NAGS
pathophysiology:
- name: Deficient urea cycle enzyme function
  description: 'This curated group entry focuses on loss of function in core urea-cycle enzymes required for nitrogen disposal.

    '
  genes:
  - preferred_term: CPS1
    term:
      id: hgnc:2323
      label: CPS1
  - preferred_term: OTC
    term:
      id: hgnc:8512
      label: OTC
  - preferred_term: ASS1
    term:
      id: hgnc:758
      label: ASS1
  - preferred_term: ASL
    term:
      id: hgnc:746
      label: ASL
  - preferred_term: ARG1
    term:
      id: hgnc:663
      label: ARG1
  - preferred_term: NAGS
    term:
      id: hgnc:17996
      label: NAGS
  biological_processes: []
  molecular_functions:
  - preferred_term: catalytic activity
    term:
      id: GO:0003824
      label: catalytic activity
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Congenital defects of the enzymes or transporters of the urea cycle cause the disease.
    explanation: Directly supports primary upstream molecular defects in urea-cycle enzymes; transporter defects are outside this entry's current subtype scope.
  downstream:
  - target: Impaired hepatic ureagenesis and ammonia accumulation
    description: Loss of catalytic enzyme function reduces urea production and permits ammonia accumulation.
    causal_link_type: DIRECT
  - target: Nitric oxide deficiency in ASL deficiency
    description: ASL loss impairs systemic nitric oxide production through reduced endogenous arginine synthesis and impaired use of extracellular arginine.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - decreased endogenous arginine synthesis
    - impaired extracellular arginine utilization for nitric oxide production
    evidence:
    - reference: PMID:22081021
      reference_title: "Requirement of argininosuccinate lyase for systemic nitric oxide production."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: |-
        Loss of Asl in both humans and mice leads to reduced NO
        synthesis, owing to both decreased endogenous arginine synthesis and an impaired
        ability to use extracellular arginine for NO production.
      explanation: Supports the human ASL-deficiency component of the subtype-specific nitric oxide branch.
    - reference: PMID:22081021
      reference_title: "Requirement of argininosuccinate lyase for systemic nitric oxide production."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: |-
        Loss of Asl in both humans and mice leads to reduced NO
        synthesis, owing to both decreased endogenous arginine synthesis and an impaired
        ability to use extracellular arginine for NO production.
      explanation: Supports the mouse-model component of the subtype-specific nitric oxide branch.
  - target: Hepatic glutathione dysregulation in ASL deficiency
    description: ASL deficiency produces a subtype-specific hepatic redox branch with glutathione depletion and altered cysteine utilization.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:38198573
      reference_title: "mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Here, we describe the \ndysregulation of glutathione biosynthesis and upstream cysteine utilization in \nASL-deficient patients and mice"
      explanation: Supports the patient component of ASL-associated glutathione and cysteine dysregulation.
    - reference: PMID:38198573
      reference_title: "mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Here, we describe the \ndysregulation of glutathione biosynthesis and upstream cysteine utilization in \nASL-deficient patients and mice"
      explanation: Supports the mouse-model component of ASL-associated glutathione and cysteine dysregulation.
  - target: Arginine and guanidino compound neurotoxicity in ARG1 deficiency
    description: ARG1 loss creates the distal urea-cycle branch dominated by hyperargininemia and progressive spastic neurologic disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "partial or complete loss of enzyme function"
      explanation: Supports ARG1 loss of enzyme function as the upstream defect for the ARG1-specific hyperargininemia branch.
- name: Impaired hepatic ureagenesis and ammonia accumulation
  description: 'The urea cycle is the main pathway for ammonia detoxification, localized to periportal hepatocytes. Reduced conversion of ammonia to urea causes accumulation of circulating ammonia and nitrogenous intermediates. Proximal mitochondrial defects (CPS1, OTC, NAGS) produce hyperammonemia with low citrulline and arginine, while distal cytosolic defects (ASS1, ASL, ARG1) cause accumulation of pathway intermediates with variable hyperammonemia.

    '
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The urea cycle is a metabolic pathway for the disposal of excess nitrogen, which arises primarily as ammonia.
    explanation: Directly supports the urea cycle as the principal ammonia detoxification pathway.
  downstream:
  - target: Hyperammonemic neurotoxicity and cerebral edema
    description: Ammonia excess drives astrocyte glutamine loading, edema, and encephalopathic brain injury.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Ammonia crosses the blood-brain barrier and is converted to glutamine in astrocytes.
  - target: Catabolic nitrogen stress exceeding residual ureagenesis
    description: Catabolic illness, fasting, surgery, or protein loading can overwhelm residual urea-cycle flux and precipitate acute decompensation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Increased endogenous protein catabolism raises nitrogen production.
  - target: Carbamoyl phosphate overflow to pyrimidine pathway
    description: In proximal defects, excess carbamoyl phosphate is diverted toward pyrimidine synthesis and orotate production.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Hyperammonemia
    description: Failed hepatic nitrogen disposal manifests clinically as hyperammonemia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:10869432
      reference_title: "In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Urea cycle disorders are a group of inborn errors of hepatic metabolism that result in often life-threatening hyperammonemia and hyperglutaminemia.
      explanation: Human in vivo flux study supports hyperammonemia as a consequence of impaired hepatic urea-cycle metabolism.
  - target: Plasma ammonia
    description: Reduced ammonia-to-urea conversion raises circulating ammonia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37938118
      reference_title: "Urea cycle disorders in critically Ill adults."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Urea cycle disorders (UCDs) cause elevations in ammonia which, when severe, cause irreversible neurologic injury.
      explanation: Supports plasma ammonia elevation as the core biochemical abnormality downstream of UCD metabolism.
  - target: Plasma glutamine
    description: Excess nitrogen is shunted into glutamine, producing hyperglutaminemia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Ammonia is incorporated into glutamine by glutamine synthetase.
    evidence:
    - reference: PMID:10869432
      reference_title: "In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Urea cycle disorders are a group of inborn errors of hepatic metabolism that result in often life-threatening hyperammonemia and hyperglutaminemia.
      explanation: Supports glutamine elevation as a paired biochemical consequence of impaired urea-cycle flux.
  - target: Plasma citrulline
    description: The position of the enzymatic block produces subtype-specific citrulline abnormalities, low in proximal defects and high in ASS1 deficiency.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:32628763
      reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA.
      explanation: Supports decreased citrulline as a proximal UCD biochemical branch, while the node context notes subtype-dependent direction.
  - target: Argininosuccinic acid
    description: ASL deficiency blocks argininosuccinate cleavage and causes argininosuccinic acid accumulation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38198573
      reference_title: "mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Patients with ASL deficiency present with argininosuccinic aciduria
      explanation: Supports argininosuccinic aciduria as the ASL-deficiency biochemical branch of UCDs.
  - target: Chronic UCD liver disease
    description: UCDs can develop chronic liver disease through incompletely resolved mechanisms downstream of the inherited urea-cycle defect.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33846069
      reference_title: "Biomarkers for liver disease in urea cycle disorders."
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: Increasingly, studies have demonstrated that children and adults with UCDs are also at risk for developing various forms of chronic liver disease
      explanation: The review links UCDs with chronic liver disease risk, but does not resolve the exact causal intermediates.
- name: Catabolic nitrogen stress exceeding residual ureagenesis
  description: 'Catabolic stressors such as infection, fasting, surgery, childbirth, or high protein intake increase endogenous protein breakdown and nitrogen load. In patients with partial residual urea-cycle function, this excess nitrogen can exceed detoxification capacity and precipitate acute hyperammonemic crises.

    '
  biological_processes:
  - preferred_term: protein catabolic process
    term:
      id: GO:0030163
      label: protein catabolic process
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:33409766
    reference_title: "Urea cycle disorders in adult patients: a tightrope walk between evidence-based medicine and expert opinion-a case series and systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: During metabolic stress induced by infection, childbirth or surgery, a catabolic phase leads to the metabolism of a large amount of proteins. This excess intake will exceed the capacity of the urea cycle, especially if it has an enzymatic deficit. A significant production of ammonia then follows.
    explanation: Adult UCD review links catabolic stress with excess protein breakdown, exceeded urea-cycle capacity, and ammonia production.
  downstream:
  - target: Hyperammonemia
    description: Excess nitrogen production during catabolism precipitates acute ammonia elevation when residual ureagenesis is insufficient.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Increased proteolysis raises ammonia substrate load.
    evidence:
    - reference: PMID:33409766
      reference_title: "Urea cycle disorders in adult patients: a tightrope walk between evidence-based medicine and expert opinion-a case series and systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: A significant production of ammonia then follows.
      explanation: Supports hyperammonemia following catabolic excess nitrogen load.
  - target: Vomiting
    description: Acute decompensation in late-onset UCDs commonly includes nausea and vomiting.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Respiratory alkalosis
    description: Hyperammonemic decompensation can present with hyperventilation and respiratory alkalosis.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Hyperammonemic neurotoxicity and cerebral edema
  description: 'Ammonia diffuses freely across the blood-brain barrier and is detoxified primarily in astrocytes by conversion to glutamine via glutamine synthetase. During hyperammonemic crises, glutamine becomes an osmolyte that drives astrocytic swelling and cytotoxic cerebral edema. This is accompanied by disrupted glutamate-glutamine cycling, excitotoxicity, impaired energy metabolism, and altered aquaporin-4 expression, culminating in encephalopathy and seizure susceptibility.

    '
  biological_processes:
  - preferred_term: glutamine biosynthetic process
    term:
      id: GO:1901704
      label: L-glutamine biosynthetic process
  - preferred_term: cellular response to osmotic stress
    term:
      id: GO:0071470
      label: cellular response to osmotic stress
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The strategy for therapy is to prevent the irreversible toxicity of high-ammonia exposure to the brain.
    explanation: Supports ammonia-mediated brain toxicity as a central downstream mechanism.
  - reference: PMID:33409766
    reference_title: "Urea cycle disorders in adult patients: a tightrope walk between evidence-based medicine and expert opinion-a case series and systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Ammonia passes into the circulation and crosses the blood–brain barrier. The ammonia will exert a direct toxic effect on the neurotransmission responsible for part of the neurological symptomatology.
    explanation: Supports CNS ammonia toxicity as a direct neurologic mechanism in UCD crises.
  downstream:
  - target: Cerebral edema
    description: Astrocyte glutamine accumulation acts as an osmolyte and increases brain volume.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Astrocytic glutamine synthetase converts ammonia and glutamate into glutamine.
    evidence:
    - reference: PMID:33409766
      reference_title: "Urea cycle disorders in adult patients: a tightrope walk between evidence-based medicine and expert opinion-a case series and systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Glutamine is the main intracellular osmole of the brain. Its accumulation causes the swelling of astrocytes during hyperammonemia
      explanation: Supports the osmotic astrocyte swelling mechanism underlying cerebral edema.
  - target: Encephalopathy
    description: Ammonia-mediated neurotransmission toxicity and astrocyte swelling produce metabolic encephalopathy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Lethargy
    description: Altered alertness is an early neurologic manifestation of ammonia toxicity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Seizures
    description: Ammonia and glutamine elevations increase seizure risk during hyperammonemic crises.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:39121557
      reference_title: "Unraveling the Link: Seizure Characteristics and Ammonia Levels in Urea Cycle Disorder During Hyperammonemic Crises."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The odds of seizures increases 2.65
      explanation: UCD cohort data quantitatively link higher ammonia with seizure risk during crises.
  - target: Coma
    description: Severe intracranial hypertension and metabolic encephalopathy can progress to coma and death.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33409766
      reference_title: "Urea cycle disorders in adult patients: a tightrope walk between evidence-based medicine and expert opinion-a case series and systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Intra cranial hypertension appears inducing coma, cerebral engagement and death of the patient.
      explanation: Supports coma as a severe downstream consequence of hyperammonemic brain swelling.
  - target: Intellectual disability
    description: Survivors of neonatal or recurrent hyperammonemic injury can develop long-term cognitive impairment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Global developmental delay
    description: Recurrent or neonatal ammonia-mediated brain injury impairs neurodevelopment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Abnormality of movement
    description: Hyperammonemia and toxic metabolite accumulation can produce increased neuromuscular tone, spasticity, and clonus.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
      explanation: GeneReviews links hyperammonemia and toxic metabolite accumulation to neuromuscular tone abnormalities and clonus, supporting the movement-abnormality branch.
- name: Carbamoyl phosphate overflow to pyrimidine pathway
  description: 'In proximal urea cycle defects, particularly OTC deficiency, carbamoyl phosphate accumulates in the mitochondrial matrix and is diverted into the cytosolic pyrimidine synthesis pathway, leading to elevated urinary orotic acid. This overflow is diagnostically useful for distinguishing OTC deficiency from CPS1 deficiency.

    '
  biological_processes:
  - preferred_term: pyrimidine nucleotide biosynthetic process
    term:
      id: GO:0006221
      label: pyrimidine nucleotide biosynthetic process
  locations:
  - preferred_term: mitochondrial matrix
    term:
      id: GO:0005759
      label: mitochondrial matrix
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: two of which, carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial matrix
    explanation: Supports the mitochondrial localization of proximal urea cycle enzymes where carbamoyl phosphate accumulates.
  downstream:
  - target: Urinary orotic acid
    description: Proximal carbamoyl phosphate excess is diverted to pyrimidine synthesis and appears diagnostically as elevated urinary orotic acid, especially in OTC deficiency.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:32628763
      reference_title: "Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The major biochemical hallmarks of OTCD include increased plasma NH3 and glutamine, decreased citrulline and increased urine OA.
      explanation: Supports increased urinary orotic acid as a proximal OTCD biomarker downstream of pyrimidine overflow.
- name: Chronic UCD liver disease
  description: 'Children and adults with UCDs can develop chronic liver disease even outside acute hyperammonemic episodes. Reported manifestations include abnormal liver enzymes, hepatomegaly, abnormal liver ultrasound, steatosis, fibrosis, cirrhosis with portal hypertension, impaired liver function, and liver failure requiring transplantation.

    '
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:33846069
    reference_title: "Biomarkers for liver disease in urea cycle disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Increasingly, studies have demonstrated that children and adults with UCDs are also at risk for developing various forms of chronic liver disease
    explanation: Human UCD cohort review supports chronic liver disease as a recognized complication across UCDs.
  downstream:
  - target: Hepatomegaly
    description: Hepatomegaly is one reported manifestation within the chronic liver disease spectrum of UCDs.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33846069
      reference_title: "Biomarkers for liver disease in urea cycle disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The manifestations of chronic liver disease in UCDs are variable and may include elevated serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), hepatomegaly, abnormal grey-scale ultrasound pattern of the liver parenchyma, hepatic steatosis, hepatic fibrosis, cirrhosis with portal hypertension, and impaired liver function
      explanation: Supports hepatomegaly as a reported manifestation of chronic UCD liver disease.
- name: Hepatic glutathione dysregulation in ASL deficiency
  description: 'In argininosuccinic aciduria (ASL deficiency), glutathione biosynthesis is dysregulated with upregulated cysteine metabolism but depleted glutathione and downregulated antioxidant pathways. This redox defect provides a molecular basis for chronic liver disease manifestations in ASL deficiency beyond episodic hyperammonemia, and represents a target for mRNA therapy approaches.

    '
  genes:
  - preferred_term: ASL
    term:
      id: hgnc:746
      label: ASL
  biological_processes:
  - preferred_term: glutathione metabolic process
    term:
      id: GO:0006749
      label: glutathione metabolic process
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:38198573
    reference_title: "mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here, we describe the dysregulation of glutathione biosynthesis and upstream cysteine utilization in ASL-deficient patients and mice
    explanation: The abstract explicitly includes ASL-deficient patients in the glutathione/cysteine dysregulation finding.
  - reference: PMID:38198573
    reference_title: "mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Human hASL mRNA encapsulated in lipid nanoparticles improved glutathione metabolism and chronic liver disease.
    explanation: Supports the preclinical mRNA-therapy component of this ASL-specific hepatic redox mechanism.
  notes: 'This mechanism is specific to ASL deficiency and explains liver disease beyond ammonia toxicity. mRNA therapy has been shown to restore hepatic glutathione to near wild-type levels in preclinical models.

    '
  downstream:
  - target: Chronic UCD liver disease
    description: ASL-associated glutathione depletion and antioxidant-pathway dysregulation contribute to the chronic liver-disease branch of argininosuccinic aciduria.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - glutathione depletion
    - down-regulated antioxidant pathways
    evidence:
    - reference: PMID:38198573
      reference_title: "mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Human hASL mRNA encapsulated in lipid nanoparticles improved glutathione \nmetabolism and chronic liver disease."
      explanation: Preclinical mRNA rescue links corrected glutathione metabolism with improved chronic liver disease in ASL deficiency.
- name: Nitric oxide deficiency in ASL deficiency
  description: 'ASL participates in the citrulline-argininosuccinate-arginine recycling pathway that channels arginine to nitric oxide synthase. ASL deficiency impairs endogenous nitric oxide production, contributing to systemic vascular and neurological phenotypes that are independent of hyperammonemia, including hypertension and neurocognitive deficits.

    '
  genes:
  - preferred_term: ASL
    term:
      id: hgnc:746
      label: ASL
  biological_processes:
  - preferred_term: nitric oxide biosynthetic process
    term:
      id: GO:0006809
      label: nitric oxide biosynthetic process
  evidence:
  - reference: PMID:22081021
    reference_title: "Requirement of argininosuccinate lyase for systemic nitric oxide production."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: |-
      Loss of Asl in both humans and mice leads to reduced NO
      synthesis, owing to both decreased endogenous arginine synthesis and an impaired
      ability to use extracellular arginine for NO production.
    explanation: The abstract directly supports reduced nitric oxide synthesis in humans with ASL deficiency.
  - reference: PMID:37490345
    reference_title: "Argininosuccinate lyase deficiency causes blood-brain barrier disruption via nitric oxide-mediated dysregulation of claudin expression."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Previously, we have shown that \nargininosuccinate lyase deficiency (ASLD) is a novel model system to investigate \ncell-autonomous, nitric oxide synthase-dependent NO deficiency."
    explanation: Supports a cell-autonomous nitric oxide deficiency mechanism in ASL-deficient systems.
  downstream:
  - target: Abnormality of movement
    description: NO-mediated central catecholamine dysregulation is associated with the late-onset movement-disorder phenotype in ASA.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - NO-mediated downregulation of central catecholamine biosynthesis
    evidence:
    - reference: PMID:38044746
      reference_title: "The incidence of movement disorder increases with age and contrasts with subtle and limited neuroimaging abnormalities in argininosuccinic aciduria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients present with developmental delay, \nepilepsy and movement disorder, associated with NO-mediated downregulation of \ncentral catecholamine biosynthesis."
      explanation: Supports the NO-linked movement-disorder branch in argininosuccinic aciduria.
  - target: Global developmental delay
    description: Developmental delay occurs within the ASA neurological phenotype associated with NO-mediated central catecholamine dysregulation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - NO-mediated downregulation of central catecholamine biosynthesis
    evidence:
    - reference: PMID:38044746
      reference_title: "The incidence of movement disorder increases with age and contrasts with subtle and limited neuroimaging abnormalities in argininosuccinic aciduria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients present with developmental delay, \nepilepsy and movement disorder, associated with NO-mediated downregulation of \ncentral catecholamine biosynthesis."
      explanation: Supports developmental delay as part of the NO-associated ASA neurological phenotype.
  - target: Seizures
    description: Epilepsy occurs within the ASA neurological phenotype associated with NO-mediated central catecholamine dysregulation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - NO-mediated downregulation of central catecholamine biosynthesis
    evidence:
    - reference: PMID:38044746
      reference_title: "The incidence of movement disorder increases with age and contrasts with subtle and limited neuroimaging abnormalities in argininosuccinic aciduria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Patients present with developmental delay, \nepilepsy and movement disorder, associated with NO-mediated downregulation of \ncentral catecholamine biosynthesis."
      explanation: Supports epilepsy/seizures as part of the NO-associated ASA neurological phenotype.
- name: Arginine and guanidino compound neurotoxicity in ARG1 deficiency
  description: 'ARG1 deficiency is a distal urea-cycle defect in which chronic hyperargininemia and related guanidino compound accumulation, rather than recurrent severe hyperammonemia alone, dominate the progressive neurologic phenotype. This subtype-specific toxic-metabolite mechanism explains spastic paraplegia-predominant disease.

    '
  genes:
  - preferred_term: ARG1
    term:
      id: hgnc:663
      label: ARG1
  biological_processes:
  - preferred_term: L-arginine catabolic process
    term:
      id: GO:0006527
      label: L-arginine catabolic process
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:26467175
    reference_title: "Arginase-1 deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia, a clinical pattern that differs strikingly from other urea cycle disorders.
    explanation: Review of clinical reports supports hyperargininemia with progressive spastic paraparesis as the ARG1-specific neurologic mechanism.
  downstream:
  - target: Plasma arginine
    description: Loss of ARG1-mediated arginine hydrolysis produces persistent hyperargininemia.
    causal_link_type: DIRECT
  - target: Spastic paraplegia
    description: Chronic arginine-related neurotoxicity underlies progressive spastic paraparesis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:26467175
      reference_title: "Arginase-1 deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: ARG1-deficient patients exhibit hyperargininemia with spastic paraparesis, progressive neurological and intellectual impairment, persistent growth retardation, and infrequent episodes of hyperammonemia
      explanation: The cited clinical review links ARG1 hyperargininemia with spastic paraparesis and progressive neurologic impairment.
phenotypes:
- name: Hyperammonemia
  frequency: VERY_FREQUENT
  description: 'Elevated plasma ammonia concentration is the defining clinical feature of UCDs. Ammonia rises especially during catabolic stress, infection, or protein loading. In neonates, levels >200 umol/L suggest IEM; after the neonatal period, >100 umol/L is concerning.

    '
  phenotype_term:
    preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The urea cycle disorders (UCDs) comprise diseases presenting with hyperammonemia that arise in either the neonatal period (about 50% of cases) or later.
    explanation: Confirms hyperammonemia as the defining clinical presentation across UCDs.
  - reference: PMID:30982989
    reference_title: "Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: UCDs cause hyperammonemia of neonatal (~50%) or late onset that can lead to intellectual disability or death
    explanation: Supports hyperammonemia as the core feature with variable age of onset.
- name: Encephalopathy
  frequency: FREQUENT
  description: 'Acute or recurrent hyperammonemic encephalopathy with altered mental status, ranging from irritability and lethargy to coma. Severity is time- and concentration-dependent.

    '
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:37938118
    reference_title: "Urea cycle disorders in critically Ill adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperammonemia, particularly if severe, causes time- and concentration-dependent neurologic injury.
    explanation: Supports severity-dependent encephalopathy from hyperammonemia.
  - reference: PMID:30982989
    reference_title: "Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: UCDs cause hyperammonemia of neonatal (~50%) or late onset that can lead to intellectual disability or death
    explanation: Supports severe neurologic consequences from hyperammonemic episodes.
- name: Seizures
  frequency: FREQUENT
  description: 'Seizures occur in approximately 13% of hyperammonemic events. Subclinical seizures are detected in 27% of encephalopathic crises without clinical seizures and 53% when clinical seizures are present. Seizure risk increases 2.65-fold per 100 umol/L ammonia increase.

    '
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:39121557
    reference_title: "Unraveling the Link: Seizure Characteristics and Ammonia Levels in Urea Cycle Disorder During Hyperammonemic Crises."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Seizures are observed in 13% of HA events. Among all HA events with concomitant EEG, subclinical seizures were identified in 27% of crises of encephalopathy without clinical seizures and 53% of crises with clinical seizures.
    explanation: Quantifies seizure prevalence during UCD crises with EEG monitoring data.
- name: Cerebral edema
  frequency: FREQUENT
  description: 'Cytotoxic cerebral edema driven by astrocytic glutamine accumulation and osmotic swelling is a life-threatening complication of severe hyperammonemic crises, contributing to raised intracranial pressure.

    '
  phenotype_term:
    preferred_term: Cerebral edema
    term:
      id: HP:0002181
      label: Cerebral edema
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The strategy for therapy is to prevent the irreversible toxicity of high-ammonia exposure to the brain.
    explanation: Supports brain injury risk from ammonia exposure; cerebral edema is a key mechanism.
- name: Intellectual disability
  frequency: FREQUENT
  description: 'Long-term neurodevelopmental impairment is common in survivors of neonatal hyperammonemic crises and in those with recurrent episodes. Outcome correlates with peak ammonia level and duration of exposure.

    '
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:30982989
    reference_title: "Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: UCDs cause hyperammonemia of neonatal (~50%) or late onset that can lead to intellectual disability or death
    explanation: Directly supports intellectual disability as a major outcome of UCDs.
- name: Lethargy
  frequency: FREQUENT
  description: 'Decreased alertness and feeding difficulty during acute metabolic decompensation. Often the earliest clinical sign of hyperammonemic crisis in neonates.

    '
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: PMID:37938118
    reference_title: "Urea cycle disorders in critically Ill adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperammonemia, particularly if severe, causes time- and concentration-dependent neurologic injury.
    explanation: Lethargy and altered mental status are dose-dependent neurologic manifestations.
- name: Vomiting
  frequency: FREQUENT
  description: 'Recurrent vomiting with poor feeding during metabolic instability is a common presenting symptom, particularly in late-onset forms.

    '
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  notes: Vomiting is a common decompensation symptom in UCDs; a direct vomiting-specific quote was not available in the currently curated abstracts.
- name: Failure to thrive
  frequency: FREQUENT
  description: 'Poor growth is common due to protein-restricted diets, recurrent catabolic crises, and feeding difficulties.

    '
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  notes: Failure to thrive is common in chronically affected patients, but no growth-specific quote was available in the currently cited abstracts.
- name: Spastic paraplegia
  frequency: OCCASIONAL
  description: 'Progressive spasticity, particularly spastic diplegia, is the predominant neurological phenotype in arginase deficiency (ARG1). This distinct presentation can lead to diagnostic confusion with cerebral palsy.

    '
  phenotype_term:
    preferred_term: Spastic paraplegia
    term:
      id: HP:0001258
      label: Spastic paraplegia
  notes: 'Predominantly associated with arginase deficiency (ARG1). Progressive spasticity is often the presenting feature rather than hyperammonemic crises.

    '
- name: Hepatomegaly
  frequency: OCCASIONAL
  description: 'Liver enlargement can occur in UCDs, particularly in ASL deficiency where chronic liver disease with fibrosis may develop. Hepatic involvement is also seen in citrin deficiency.

    '
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: PMID:33846069
    reference_title: "Biomarkers for liver disease in urea cycle disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The manifestations of chronic liver disease in UCDs are variable and may include elevated serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST), hepatomegaly, abnormal grey-scale ultrasound pattern of the liver parenchyma, hepatic steatosis, hepatic fibrosis, cirrhosis with portal hypertension, and impaired liver function
    explanation: Supports hepatomegaly as a reported manifestation within the chronic liver disease spectrum of UCDs.
- name: Respiratory alkalosis
  frequency: OCCASIONAL
  description: 'Hyperventilation-driven respiratory alkalosis can be an early sign of hyperammonemia, as ammonia stimulates the central respiratory center. This may be the initial metabolic finding before frank metabolic crisis.

    '
  phenotype_term:
    preferred_term: Respiratory alkalosis
    term:
      id: HP:0001950
      label: Respiratory alkalosis
  notes: Respiratory alkalosis is a recognized early hyperammonemia sign, but a direct quote was not available in the currently cited abstracts.
- name: Coma
  frequency: OCCASIONAL
  description: 'Hyperammonemic coma represents the most severe neurological presentation, occurring primarily in neonatal-onset forms. Prognosis is very poor when ammonia exceeds 1000 umol/L with prolonged coma.

    '
  phenotype_term:
    preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: excessive ammonia leads to life-threatening conditions
    explanation: Supports life-threatening neurological deterioration from hyperammonemia.
- name: Global developmental delay
  frequency: FREQUENT
  description: 'Developmental delay is common in children with UCDs, particularly those with neonatal-onset disease or recurrent hyperammonemic episodes.

    '
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:30982989
    reference_title: "Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: UCDs cause hyperammonemia of neonatal (~50%) or late onset that can lead to intellectual disability or death
    explanation: Supports neurodevelopmental morbidity as a major UCD complication.
- name: Abnormality of movement
  frequency: OCCASIONAL
  description: 'Hyperammonemia and toxic metabolite accumulation can produce increased neuromuscular tone, spasticity, and ankle clonus during severe decompensation.

    '
  phenotype_term:
    preferred_term: Abnormality of movement
    term:
      id: HP:0100022
      label: Abnormality of movement
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
    explanation: GeneReviews directly supports neuromuscular tone abnormalities, spasticity, and ankle clonus as downstream consequences of hyperammonemia and toxic metabolite accumulation.
biochemical:
- name: Plasma ammonia
  presence: INCREASED
  frequency: VERY_FREQUENT
  context: 'Elevated plasma ammonia is the cardinal biochemical finding in UCDs. In neonates, levels >200 umol/L suggest IEM; post-neonatal, >100 umol/L is concerning. Very poor prognosis is associated with levels >1000 umol/L.

    '
  evidence:
  - reference: PMID:37938118
    reference_title: "Urea cycle disorders in critically Ill adults."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Urea cycle disorders (UCDs) cause elevations in ammonia which, when severe, cause irreversible neurologic injury.
    explanation: Confirms ammonia elevation as the core biochemical abnormality causing injury.
- name: Plasma glutamine
  presence: INCREASED
  frequency: VERY_FREQUENT
  context: 'Glutamine rises as an alternative nitrogen sink when ureagenesis is impaired. In brain, glutamine accumulation in astrocytes drives osmotic swelling and cerebral edema. Each 100 umol/L increase in plasma glutamine increases seizure odds by 1.14-fold during crises.

    '
  evidence:
  - reference: PMID:39121557
    reference_title: "Unraveling the Link: Seizure Characteristics and Ammonia Levels in Urea Cycle Disorder During Hyperammonemic Crises."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 1.14 (95% CI, 1.04 to 1.25) times for every 100 μmol/L increase in glutamine
    explanation: Quantifies glutamine as a seizure risk biomarker during hyperammonemic crises.
- name: Plasma citrulline
  presence: DECREASED
  frequency: FREQUENT
  context: 'Low plasma citrulline is characteristic of proximal urea cycle defects (CPS1 and OTC deficiency), reflecting impaired mitochondrial citrulline production. In contrast, citrulline is markedly elevated in ASS1 deficiency (citrullinemia type I).

    '
  notes: 'Direction of change is subtype-dependent: decreased in proximal defects, markedly increased in citrullinemia type I.

    '
- name: Urinary orotic acid
  presence: INCREASED
  frequency: FREQUENT
  context: 'Elevated urinary orotic acid is a key diagnostic biomarker for OTC deficiency, resulting from diversion of accumulated mitochondrial carbamoyl phosphate into the cytosolic pyrimidine synthesis pathway. This finding distinguishes OTC deficiency from CPS1 deficiency.

    '
  notes: Orotic acid elevation is a key OTC biomarker, but a direct orotic-acid quote was not available in the currently cited abstracts.
- name: Plasma arginine
  presence: DECREASED
  frequency: FREQUENT
  context: 'Arginine is typically low in most UCDs due to impaired urea cycle flux, requiring supplementation. In arginase deficiency (ARG1), arginine is markedly elevated due to failure of the terminal hydrolysis step.

    '
  notes: 'Direction is subtype-dependent: decreased in most UCDs, markedly increased in arginase deficiency.

    '
- name: Argininosuccinic acid
  presence: INCREASED
  frequency: OCCASIONAL
  context: 'Elevated plasma and urinary argininosuccinic acid is the pathognomonic biomarker for ASL deficiency (argininosuccinic aciduria). It may be detected on newborn screening.

    '
  notes: Argininosuccinic acid elevation is pathognomonic for ASL deficiency; no direct biomarker-specific quote was available in the currently cited abstracts.
genetic:
- name: Ornithine transcarbamylase (OTC) deficiency
  features: 'OTC deficiency is the most common UCD, with X-linked inheritance. Hemizygous males typically present with severe neonatal hyperammonemia. Heterozygous females may be asymptomatic or present with variable late-onset disease depending on X-inactivation patterns. OTC is a mitochondrial matrix enzyme that converts carbamoyl phosphate and ornithine to citrulline.

    '
  gene_term:
    preferred_term: OTC
    term:
      id: hgnc:8512
      label: OTC
  inheritance:
  - name: X-linked inheritance
    evidence:
    - reference: PMID:31110235
      reference_title: "Urea cycle disorders-update."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Congenital defects of the enzymes or transporters of the urea cycle cause the disease.
      explanation: Supports inherited enzymatic defects as the basis of UCDs; OTC is X-linked.
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ornithine transcarbamylase are present in the mitochondrial matrix
    explanation: Confirms OTC localization and its role in the urea cycle.
- name: Carbamoyl phosphate synthetase I (CPS1) deficiency
  features: 'CPS1 catalyzes the first committed step of the urea cycle in the mitochondrial matrix, converting ammonia and bicarbonate to carbamoyl phosphate. Deficiency causes severe neonatal hyperammonemia. CPS1 requires N-acetylglutamate (NAG) as an obligate allosteric activator.

    '
  gene_term:
    preferred_term: CPS1
    term:
      id: hgnc:2323
      label: CPS1
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:31110235
      reference_title: "Urea cycle disorders-update."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Congenital defects of the enzymes or transporters of the urea cycle cause the disease.
      explanation: Supports congenital enzymatic defects as the genetic basis.
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: carbamoylphosphate synthetase 1 and ornithine transcarbamylase are present in the mitochondrial matrix
    explanation: Directly identifies CPS1 as a mitochondrial urea cycle enzyme.
- name: Argininosuccinate synthetase (ASS1) deficiency
  features: 'ASS1 deficiency causes citrullinemia type I. ASS1 catalyzes the cytosolic condensation of citrulline and aspartate to form argininosuccinate. Deficiency results in marked elevation of plasma citrulline and variable hyperammonemia.

    '
  gene_term:
    preferred_term: ASS1
    term:
      id: hgnc:758
      label: ASS1
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:31110235
      reference_title: "Urea cycle disorders-update."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: argininosuccinate synthetase, argininosuccinate lyase and arginase 1) are present in the cytoplasm
      explanation: Confirms ASS1 as a cytosolic urea cycle enzyme with congenital deficiency.
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: argininosuccinate synthetase, argininosuccinate lyase and arginase 1) are present in the cytoplasm
    explanation: Directly identifies ASS1 as a cytosolic urea cycle enzyme.
- name: Argininosuccinate lyase (ASL) deficiency
  features: 'ASL deficiency causes argininosuccinic aciduria. ASL cleaves argininosuccinate to arginine and fumarate. Beyond hyperammonemia, ASL deficiency has systemic manifestations including chronic liver disease via glutathione dysregulation, nitric oxide deficiency, and neurocognitive deficits that are independent of ammonia levels.

    '
  gene_term:
    preferred_term: ASL
    term:
      id: hgnc:746
      label: ASL
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:31110235
      reference_title: "Urea cycle disorders-update."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Congenital defects of the enzymes or transporters of the urea cycle cause the disease.
      explanation: Supports congenital enzymatic defects as the genetic basis.
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: argininosuccinate synthetase, argininosuccinate lyase and arginase 1) are present in the cytoplasm
    explanation: Directly identifies ASL as a cytosolic urea cycle enzyme.
- name: Arginase 1 (ARG1) deficiency
  features: 'ARG1 deficiency (argininemia) is distinct from other UCDs, often presenting with progressive spastic diplegia rather than typical hyperammonemic crises. ARG1 hydrolyzes arginine to ornithine and urea in the final step of the urea cycle. Elevated arginine and guanidino compounds are thought to contribute to the spasticity phenotype.

    '
  gene_term:
    preferred_term: ARG1
    term:
      id: hgnc:663
      label: ARG1
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:31110235
      reference_title: "Urea cycle disorders-update."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Congenital defects of the enzymes or transporters of the urea cycle cause the disease.
      explanation: Supports congenital enzymatic defects as the genetic basis.
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: arginase 1) are present in the cytoplasm
    explanation: Identifies ARG1 as a cytosolic urea cycle enzyme.
- name: N-Acetylglutamate synthase (NAGS) deficiency
  features: 'NAGS produces N-acetylglutamate, the obligate allosteric activator of CPS1. NAGS deficiency phenocopies CPS1 deficiency with severe neonatal hyperammonemia. Uniquely among UCDs, NAGS deficiency is treatable with carglumic acid, a synthetic NAG analog that directly activates CPS1.

    '
  gene_term:
    preferred_term: NAGS
    term:
      id: hgnc:17996
      label: NAGS
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:31110235
      reference_title: "Urea cycle disorders-update."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: N-acetylglutamate synthase and at least two transporter proteins are essential to urea cycle function.
      explanation: Confirms NAGS as essential to urea cycle function.
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: N-acetylglutamate synthase and at least two transporter proteins are essential to urea cycle function.
    explanation: Directly identifies NAGS as essential for urea cycle function.
treatments:
- name: Protein-restricted diet
  description: 'Controlled protein intake to reduce nitrogen load while preserving growth is the cornerstone of chronic UCD management. Natural protein is limited and supplemented with essential amino acid mixtures to maintain adequate nutrition and growth.

    '
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  - preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  target_mechanisms:
  - target: Catabolic nitrogen stress exceeding residual ureagenesis
    treatment_effect: MODULATES
    description: Controlled protein intake reduces nitrogen substrate load while preserving enough protein for growth.
    evidence:
    - reference: PMID:11148548
      reference_title: "The nutritional management of urea cycle disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The protein intake should be adjusted to take account of the inborn error and its severity and the patient's age, growth rate, and individual preferences.
      explanation: Supports dietary titration to the biochemical defect and growth needs.
  evidence:
  - reference: PMID:11148548
    reference_title: "The nutritional management of urea cycle disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diet is one of the mainstays of the treatment of patients with urea cycle disorders.
    explanation: Directly supports protein-restricted diet as core UCD management.
- name: Nitrogen scavenger therapy
  description: 'Sodium phenylbutyrate is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine, providing an alternative renal route for waste nitrogen excretion. Glycerol phenylbutyrate is a newer palatable formulation. Sodium benzoate conjugates with glycine to form hippurate for renal excretion.

    '
  treatment_term:
    preferred_term: nitrogen scavenger therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  - preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  target_mechanisms:
  - target: Impaired hepatic ureagenesis and ammonia accumulation
    treatment_effect: BYPASSES
    description: Benzoate and phenylacetate/phenylbutyrate create alternative renal nitrogen-excretion routes that bypass the blocked urea cycle.
    evidence:
    - reference: PMID:33409766
      reference_title: "Urea cycle disorders in adult patients: a tightrope walk between evidence-based medicine and expert opinion-a case series and systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Alternative pathways to reduce ammonia production and accelerate elimination. Ammonia is diverted to the glycine and hippuric acid pathway by benzoate, and to the glutamine and phenylacetylglutamine pathway allowing elimination in the urine without passing through the urea cycle
      explanation: Supports the bypass mechanism of nitrogen scavenger therapy.
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We review here the current concepts of the pathogenesis, diagnostics, including genetics and treatment of UCDs.
    explanation: Supports nitrogen scavenger therapy as part of standard UCD treatment.
- name: Arginine and citrulline supplementation
  description: 'Arginine supplementation replaces the amino acid that cannot be synthesized endogenously in most UCDs (except ARG1 deficiency). Citrulline supplementation may be preferable as it bypasses intestinal and hepatic first-pass metabolism and has been associated with lower mean ammonia concentrations compared to arginine alone.

    '
  treatment_term:
    preferred_term: nutritional supplementation
    term:
      id: MAXO:0000106
      label: nutritional supplementation
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  target_mechanisms:
  - target: Impaired hepatic ureagenesis and ammonia accumulation
    treatment_effect: MODULATES
    description: Arginine and citrulline supplementation replenish downstream urea-cycle intermediates and support residual nitrogen flux, except in ARG1 deficiency where arginine is contraindicated.
    evidence:
    - reference: PMID:10869432
      reference_title: "In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Urea synthesis is altered by alternative route medications and arginine supplementation to the degree that is to be expected from theory.
      explanation: Human isotope study supports arginine supplementation as a measurable modifier of urea synthesis.
  evidence:
  - reference: PMID:11148548
    reference_title: "The nutritional management of urea cycle disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Most patients, except those with arginase deficiency, will need supplements of arginine
    explanation: Supports arginine supplementation as standard for most UCDs while excluding ARG1 deficiency.
  notes: 'Citrulline supplementation was associated with mean ammonia of 35.9 umol/L versus 49.8 umol/L with arginine in a retrospective cohort. Arginine is contraindicated in ARG1 deficiency.

    '
- name: Carglumic acid
  description: 'Carglumic acid (Carbaglu) is a synthetic analog of N-acetylglutamate that directly activates CPS1. It is specifically indicated for NAGS deficiency and is also used for hyperammonemia in organic acidemias. It provides pharmacological bypass of the NAGS enzyme deficiency.

    '
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  target_mechanisms:
  - target: Impaired hepatic ureagenesis and ammonia accumulation
    treatment_effect: ACTIVATES
    description: Carglumic acid replaces the missing N-acetylglutamate signal and activates CPS1-dependent ureagenesis in NAGS deficiency.
    evidence:
    - reference: PMID:33409766
      reference_title: "Urea cycle disorders in adult patients: a tightrope walk between evidence-based medicine and expert opinion-a case series and systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: N-Carbamoyl-l-glutamic acid (NCG or Carbaglu®) is a structural analogue of N-acetyl glutamate (NAG) that restores urea cycle function in inherited NAGS and CPS1 deficiency
      explanation: Supports carglumic acid as a NAG analog that restores/activates urea-cycle function in NAGS/CPS1 deficiency contexts.
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: N-acetylglutamate synthase and at least two transporter proteins are essential to urea cycle function.
    explanation: NAGS produces the obligate CPS1 activator; carglumic acid replaces this function.
- name: Acute hyperammonemia management
  description: 'Emergency management includes cessation of protein intake, high-calorie glucose infusion to reverse catabolism, intravenous nitrogen scavengers (sodium benzoate, sodium phenylacetate), and arginine supplementation. When ammonia exceeds 500 umol/L or encephalopathy is present, extracorporeal clearance with continuous renal replacement therapy (CRRT) is recommended.

    '
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  - preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  - preferred_term: Cerebral edema
    term:
      id: HP:0002181
      label: Cerebral edema
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  - preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  target_mechanisms:
  - target: Hyperammonemic neurotoxicity and cerebral edema
    treatment_effect: MODULATES
    description: Acute management lowers ammonia production and increases endogenous or extracorporeal ammonia clearance to prevent irreversible brain injury.
    evidence:
    - reference: PMID:37938118
      reference_title: "Urea cycle disorders in critically Ill adults."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Management of UCDs emphasizes decreasing ongoing ammonia production, avoiding catabolism, and supporting endogenous and exogenous ammonia clearance.
      explanation: Supports the multi-pronged acute ammonia-lowering strategy.
  evidence:
  - reference: PMID:31110235
    reference_title: "Urea cycle disorders-update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The strategy for therapy is to prevent the irreversible toxicity of high-ammonia exposure to the brain.
    explanation: Supports urgent ammonia-lowering treatment during crises.
- name: Liver transplantation
  description: 'Liver transplantation remains the only curative option for severe UCDs, restoring full urea cycle capacity. It is indicated for patients with recurrent severe hyperammonemic crises despite maximal medical therapy. Benefits include elimination of hyperammonemia risk, dietary liberalization, and improved quality of life, but carry lifelong immunosuppression requirements.

    '
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  - preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  target_mechanisms:
  - target: Deficient urea cycle enzyme function
    treatment_effect: RESTORES
    description: Orthotopic liver transplantation replaces deficient hepatic urea-cycle enzyme activity at the organ level.
    evidence:
    - reference: PMID:11148551
      reference_title: "Long-term correction of urea cycle disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Long-term correction of urea cycle disorders is achieved by correction of the enzymatic defect in hepatocytes.
      explanation: Supports transplantation as correction of the hepatic enzymatic defect.
  - target: Impaired hepatic ureagenesis and ammonia accumulation
    treatment_effect: RESTORES
    description: Transplanted liver restores hepatic ureagenesis capacity and reduces recurrent hyperammonemia risk.
  evidence:
  - reference: PMID:11148551
    reference_title: "Long-term correction of urea cycle disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Currently, orthotopic liver transplantation is the primary means of achieving this correction.
    explanation: Directly supports liver transplantation as a long-term corrective therapy for severe UCDs.
- name: Newborn screening
  description: 'Some UCDs are detectable through expanded newborn screening by tandem mass spectrometry. Citrullinemia type I (elevated citrulline) and ASL deficiency (elevated argininosuccinic acid) are most reliably detected. Early identification enables pre-symptomatic treatment initiation and prevention of neonatal crises.

    '
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  - preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  - preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:30982989
    reference_title: "Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: experience on newborn screening for some UCDs has widened
    explanation: Confirms expanding newborn screening programs for UCD detection.
progression:
- notes: 'Disease progression follows a characteristic pattern: (1) inherited enzyme deficiency reduces hepatic ureagenesis capacity; (2) catabolic triggers (infection, fasting, surgery, protein loading) precipitate ammonia accumulation; (3) ammonia crosses the blood-brain barrier and is converted to glutamine in astrocytes, driving osmotic swelling and cerebral edema; (4) encephalopathy, seizures, and neurological injury develop if ammonia is not rapidly controlled. Chronic complications include progressive intellectual disability, movement disorders, and in some subtypes (ASL deficiency), liver disease. Late-onset forms may remain undiagnosed until adulthood, presenting during windows of physiological stress.'
references:
- reference: DOI:10.1002/jimd.12609
  findings: []
- reference: DOI:10.1002/jimd.12807
  findings: []
- reference: DOI:10.1007/s11604-023-01396-0
  findings: []
- reference: DOI:10.1016/j.pediatrneurol.2024.06.013
  findings: []
- reference: DOI:10.1126/scitranslmed.adh1334
  findings: []
- reference: DOI:10.1186/s13023-023-02800-8
  findings: []
- reference: DOI:10.1186/s13023-025-03625-3
  findings: []
- reference: DOI:10.3390/app14041647
  findings: []
- reference: DOI:10.3390/biom13020396
  findings: []
- reference: DOI:10.3390/metabo15070446
  findings: []
- reference: DOI:10.3390/metabo15090573
  findings: []
- reference: DOI:10.3390/nu16010013
  findings: []
notes: 'UCDs are a heterogeneous group with incidence of approximately 1 in 35,000 births. The 2019 revised European guidelines (PMID:30982989) remain the primary reference for diagnosis and management. Key advances include quantitative seizure risk modeling showing 2.65-fold increased odds per 100 umol/L ammonia (PMID:39121557), identification of glutathione dysregulation in ASL deficiency, and development of gene and mRNA therapy approaches. OTC deficiency is the most common subtype, accounting for approximately 50% of cases. Adult-onset presentations during catabolic stress are increasingly recognized. The field is moving toward hepatocyte-targeted gene and RNA therapies, though liver transplantation remains the only curative option currently available.

  '

📚

References & Deep Research

References

12

DOI:10.1002/jimd.12609

No top-level findings curated for this source.

DOI:10.1002/jimd.12807

No top-level findings curated for this source.

DOI:10.1007/s11604-023-01396-0

No top-level findings curated for this source.

DOI:10.1016/j.pediatrneurol.2024.06.013

No top-level findings curated for this source.

DOI:10.1126/scitranslmed.adh1334

No top-level findings curated for this source.

DOI:10.1186/s13023-023-02800-8

No top-level findings curated for this source.

DOI:10.1186/s13023-025-03625-3

No top-level findings curated for this source.

DOI:10.3390/app14041647

No top-level findings curated for this source.

DOI:10.3390/biom13020396

No top-level findings curated for this source.

DOI:10.3390/metabo15070446

No top-level findings curated for this source.

DOI:10.3390/metabo15090573

No top-level findings curated for this source.

DOI:10.3390/nu16010013

No top-level findings curated for this source.

Deep Research

2

Disorder ▸

Disorder

Name: Urea Cycle Disorder
Category: Genetic
Existing deep-research providers: falcon
Existing evidence reference count in YAML: 11

Key Pathophysiology Nodes

Impaired urea cycle flux
Hyperammonemic neurotoxicity

Citation Inventory (for evidence mapping)

DOI:10.1002/jimd.12609
DOI:10.1002/jimd.12807
DOI:10.1007/s11604-023-01396-0
DOI:10.1016/j.pediatrneurol.2024.06.013
DOI:10.1126/scitranslmed.adh1334
DOI:10.1186/s13023-023-02800-8
DOI:10.1186/s13023-025-03625-3
DOI:10.26182/fbbe-3162
DOI:10.3390/app14041647
DOI:10.3390/biom13020396
DOI:10.3390/metabo15070446
DOI:10.3390/metabo15090573
DOI:10.3390/nu16010013

Falcon ▸

Disease Pathophysiology Research Template

Edison Scientific Literature 44 citations 2026-02-17T00:13:57.176775

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

Disease Name: Urea Cycle Disorder
MONDO ID: (if available)
Category: Genetic

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Urea Cycle Disorder. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

What are the primary pathophysiological mechanisms?
What molecular pathways are dysregulated?
What cellular processes are affected?

2. Key Molecular Players

Genes/Proteins: Which genes are causally involved or implicated?
Chemical Entities: What metabolites, drugs, or small molecules are relevant?
Cell Types: Which cell types are primarily affected?
Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

What biological processes (GO terms) are disrupted?
Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

Where in the cell do key processes occur?
Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

What is the sequence of events from initial trigger to clinical manifestation?
Are there distinct stages or phases?

6. Phenotypic Manifestations

What are the key clinical phenotypes?
How do they relate to the underlying mechanisms?

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic claims
Prioritize recent reviews and landmark papers
Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Pathophysiology Research Report — Urea Cycle Disorders (UCDs) (Genetic)

Scope and disease definition

Urea cycle disorders (UCDs) are inborn errors of metabolism caused by deficiency of one of the urea-cycle enzymes or associated transporters, impairing hepatic ureagenesis and leading to accumulation of neurotoxic ammonia (hyperammonemia). The urea cycle is described as “the main pathway for ammonia detoxification,” localized to “periportal hepatocytes,” and canonical UCD genes include NAGS, CPS1, OTC, ASS1, ASL, ARG1, SLC25A15 (HHH syndrome), SLC25A13 (citrin deficiency) (yin2024asurvivalguide pages 16-19). Contemporary gene-therapy reviews similarly frame UCDs as liver-centered diseases with a “permanent risk of hyperammonaemic decompensation” and neurological sequelae/death without rapid treatment; conventional therapy reduces but does not eliminate decompensation risk, and liver transplantation remains the only curative therapy (Duff et al., Apr 2024; https://doi.org/10.1002/jimd.12609) (duff2024genetherapyfor pages 1-2).

MONDO ID: Not available in retrieved evidence.

1. Core pathophysiology (molecular/cellular mechanisms)

1.1 Primary mechanism: failure of hepatic ureagenesis → hyperammonemia

Ammonia is a byproduct of protein metabolism and is definitively eliminated by hepatic urea synthesis; the urea cycle’s high-capacity “workhorse” function is required to prevent systemic ammonia accumulation (yin2024asurvivalguide pages 16-19). When urea-cycle flux is impaired by enzymatic/transporter defects, ammonia rises and alternative “first-line ammonia scavenging” via amino-acid/glutamine synthesis has limited capacity compared with ureagenesis (concept discussed in broader hyperammonemia/urea-synthesis literature) (yin2024asurvivalguide pages 16-19).

Key biochemical patterns by defect (examples): - Proximal (mitochondrial) defects (CPS1, OTC, NAGS): hyperammonemia with low citrulline/arginine and high glutamine; OTC classically shows elevated urinary orotic acid due to carbamoyl phosphate diversion to pyrimidine synthesis (fenves2025gastricbypassassociated pages 12-15, fenves2025gastricbypassassociated pages 10-12, erdal2025aminoacidmetabolism pages 4-4). - Distal (cytosolic) defects (ASS1, ASL, ARG1): accumulation of pathway intermediates (e.g., citrulline in ASS1; argininosuccinate in ASL; arginine/guanidino compounds in ARG1), with variable hyperammonemia (nteli2024argininemiapathophysiologyand pages 2-3, enokizono2023neuroimagingfindingsof pages 4-6).

1.2 Brain pathophysiology of hyperammonemia (central mechanism of morbidity)

A key, repeatedly supported concept in UCD neurotoxicity is that ammonia crosses the blood–brain barrier and is detoxified primarily in astrocytes by conversion to glutamine. In UCD-related crises, glutamine becomes an osmolyte that drives astrocytic swelling and cerebral edema.

Direct UCD-specific mechanistic statements (2023–2024): - Neuroimaging review: ammonia “diffuses freely across the blood–brain barrier” and is converted to glutamine, “which is osmotically active,” leading to astrocytic swelling and cytotoxic cerebral edema; ^1H-MRS shows increased Glx and decreased myo-inositol (an osmotic buffer) proportional to severity (Enokizono et al., Feb 2023; https://doi.org/10.1007/s11604-023-01396-0) (enokizono2023neuroimagingfindingsof pages 4-6). - UCD seizure cohort: ammonia is metabolized to glutamine in brain; glutamine accumulation increases osmolarity “leading to cerebral edema.” The authors enumerate mechanistic contributors to seizures during hyperammonemia, including “excitotoxicity,” altered aquaporin-4, “disrupted energy/glucose metabolism,” and “impaired nitric oxide synthesis” (Chanvanichtrakool et al., Oct 2024; https://doi.org/10.1016/j.pediatrneurol.2024.06.013) (chanvanichtrakool2024unravelingthelink pages 1-3).

Additional mechanistic detail from hyperammonemia literature (relevant to UCD crises): - A 2023 review of hyperammonemic encephalopathy highlights astrocyte-localized glutamine synthetase (GS) and supports a causal role of glutamine in edema by noting that pharmacologic GS inhibition can prevent ammonia-induced astrocyte swelling/brain edema; it further links ammonia/glutamine to mitochondrial permeability dysfunction, oxidative/nitrosative stress, neurotransmission disruption, and inflammatory contributions (Lu, Feb 2023; https://doi.org/10.3390/biom13020396) (lu2023cellularpathogenesisof pages 1-2, lu2023cellularpathogenesisof pages 2-4).

Systems-level consequences (brain): - Osmotic/edema: astrocyte glutamine accumulation → swelling → cerebral edema and intracranial pressure risk (chanvanichtrakool2024unravelingthelink pages 1-3, enokizono2023neuroimagingfindingsof pages 4-6). - Neurotransmission/excitability: increased Glx (MRS), impaired glutamate–glutamine cycling, and excitotoxicity are implicated in seizure susceptibility (chanvanichtrakool2024unravelingthelink pages 1-3, enokizono2023neuroimagingfindingsof pages 4-6, lu2023cellularpathogenesisof pages 2-4). - Energy metabolism: disrupted glucose/energy metabolism during hyperammonemia is explicitly cited as a seizure mechanism in UCD crises (chanvanichtrakool2024unravelingthelink pages 1-3). - Nitric oxide pathway disruption: “impaired nitric oxide synthesis” is named as a seizure-related mechanism in UCD crises; this is especially relevant in ASL deficiency, which is associated with systemic phenotypes beyond hyperammonemia (chanvanichtrakool2024unravelingthelink pages 1-3, duff2024genetherapyfor pages 2-4).

1.3 Liver pathophysiology beyond ammonia: oxidative stress/redox and chronic liver disease (ASL deficiency exemplar)

A major 2024 mechanistic advance is a more explicit link between ASL deficiency (argininosuccinic aciduria, ASA) and hepatic glutathione dysregulation. Gurung et al. (Science Translational Medicine, Jan 2024; https://doi.org/10.1126/scitranslmed.adh1334) report dysregulated glutathione biosynthesis and upstream cysteine utilization in ASL-deficient patients and mice; cysteine metabolism is upregulated while glutathione is depleted and antioxidant pathways are downregulated (gurung2024mrnatherapycorrects pages 1-3). This provides a molecular basis for chronic liver disease manifestations in ASA beyond episodic hyperammonemia.

2. Key molecular players

2.1 Genes/proteins (causal)

Core urea-cycle and related genes explicitly enumerated in the retrieved UCD sources: - NAGS (N-acetylglutamate synthase): produces N-acetylglutamate (NAG), obligate CPS1 activator; arginine activates NAGS (fenves2025gastricbypassassociated pages 12-15, erdal2025aminoacidmetabolism pages 4-4). - CPS1 (carbamoyl phosphate synthetase 1): first mitochondrial urea-cycle step (yin2024asurvivalguide pages 16-19, meier2024noncirrhotichyperammonemiaand pages 13-16). - OTC (ornithine transcarbamylase): mitochondrial conversion of carbamoyl phosphate + ornithine → citrulline; deficiency linked to orotic acid elevation (fenves2025gastricbypassassociated pages 10-12, erdal2025aminoacidmetabolism pages 4-4). - ASS1 (argininosuccinate synthase 1) (citrullinemia type I) (yin2024asurvivalguide pages 16-19). - ASL (argininosuccinate lyase) (argininosuccinic aciduria) (yin2024asurvivalguide pages 16-19, gurung2024mrnatherapycorrects pages 1-3). - ARG1 (arginase 1) (argininemia): hydrolyzes arginine → ornithine + urea; mutations cause hyperargininemia and progressive spasticity phenotype (nteli2024argininemiapathophysiologyand pages 2-3). - SLC25A15 (ORNT1; ornithine transporter) (HHH syndrome) (yin2024asurvivalguide pages 16-19, erdal2025aminoacidmetabolism pages 4-4). - SLC25A13 (citrin; aspartate–glutamate carrier) (citrin deficiency) (yin2024asurvivalguide pages 16-19).

2.2 Chemical entities / metabolites

Core metabolites and diagnostic/effector molecules: - Ammonia (NH3/NH4+): proximal toxic effector driving neurotoxicity (yin2024asurvivalguide pages 16-19, enokizono2023neuroimagingfindingsof pages 4-6). - Glutamine: astrocytic ammonia sink/osmolyte; seizure risk biomarker during crises (chanvanichtrakool2024unravelingthelink pages 1-3, enokizono2023neuroimagingfindingsof pages 4-6). - Citrulline: urea-cycle intermediate; low in proximal defects; supplementation used therapeutically (yin2024asurvivalguide pages 16-19, imbard2023citrullineinthe pages 1-2). - Arginine: urea-cycle intermediate and NAGS activator; supplementation used therapeutically except in ARG1 deficiency; also implicated as major driver in ARG1-D pathophysiology (nteli2024argininemiapathophysiologyand pages 2-3, imbard2023citrullineinthe pages 10-11). - Orotic acid: elevated in OTC deficiency via carbamoyl phosphate overflow into pyrimidine pathway (fenves2025gastricbypassassociated pages 10-12, erdal2025aminoacidmetabolism pages 4-4).

Therapeutics and nitrogen scavengers: - Sodium phenylbutyrate → phenylacetate → phenylacetylglutamine: alternative nitrogen excretion; phenylacetate “conjugates with glutamine… to form phenylacetylglutamine,” renally excreted (mechanism-of-action text) (burlina2023longtermmanagementof pages 5-8). - Sodium benzoate (nitrogen scavenger) used acutely and chronically (yin2024asurvivalguide pages 16-19).

Emerging biomarker/theranostic (ASA): - [18F]FSPG PET radiotracer ((S)-4-(3-18F-fluoropropyl)-L-glutamate) used as noninvasive marker of glutathione dysregulation and treatment response in ASL deficiency (gurung2024mrnatherapycorrects pages 3-4, gurung2024mrnatherapycorrects pages 7-9, gurung2024mrnatherapycorrects pages 1-3).

2.3 Cell types (primary)

Periportal hepatocytes: principal site of urea-cycle enzyme expression and ureagenesis (yin2024asurvivalguide pages 16-19, duff2024genetherapyfor pages 2-4).
Astrocytes: primary brain ammonia detoxification cells (via glutamine synthetase) and central mediators of swelling/edema (enokizono2023neuroimagingfindingsof pages 4-6, lu2023cellularpathogenesisof pages 2-4).

2.4 Anatomical locations

Liver (periportal zones): urea-cycle compartment; key target for gene/RNA therapies because it receives ~25% cardiac output and has fenestrated endothelium enabling hepatocyte access (duff2024genetherapyfor pages 2-4).
Brain: blood–brain barrier, astrocytes, neuronal networks; imaging shows metabolic shifts during crises (enokizono2023neuroimagingfindingsof pages 4-6).

3. Dysregulated pathways and biological processes (GO-oriented)

(Representative GO-style terms; intended for knowledge-base annotation)

3.1 Biological processes

Urea cycle / ureagenesis; ammonia detoxification (impaired) (yin2024asurvivalguide pages 16-19, duff2024genetherapyfor pages 1-2).
Glutamine biosynthetic process / ammonia assimilation (astrocytic GS-mediated; compensatory but pathologic via osmotic effects) (enokizono2023neuroimagingfindingsof pages 4-6, lu2023cellularpathogenesisof pages 2-4).
Osmoregulation / cellular response to osmotic stress (glutamine-driven astrocyte swelling, cerebral edema) (chanvanichtrakool2024unravelingthelink pages 1-3, enokizono2023neuroimagingfindingsof pages 4-6).
Regulation of neurotransmitter levels; glutamate–glutamine cycle (disrupted; excitotoxicity risk, seizures) (chanvanichtrakool2024unravelingthelink pages 1-3, lu2023cellularpathogenesisof pages 2-4).
Mitochondrial function / cellular energy metabolism (glucose/ATP pathways) (disrupted during crises) (chanvanichtrakool2024unravelingthelink pages 1-3, lu2023cellularpathogenesisof pages 2-4).
Nitric oxide biosynthetic process (impaired nitric oxide synthesis named as seizure mechanism) (chanvanichtrakool2024unravelingthelink pages 1-3).
Glutathione metabolic process / antioxidant defense (notably dysregulated in ASL deficiency; liver disease mechanism) (gurung2024mrnatherapycorrects pages 1-3).

3.2 Dysregulated molecular pathways (conceptual)

NAGS→NAG→CPS1 activation axis: arginine deficiency can reduce NAG and CPS1 activity; NAGS deficiency phenocopies CPS1 deficiency (fenves2025gastricbypassassociated pages 12-15).
Carbamoyl phosphate overflow→orotate (pyrimidine synthesis): mechanistic basis for orotic acid elevation in OTC dysfunction (fenves2025gastricbypassassociated pages 10-12).

4. Cellular components (GO-CC oriented)

Mitochondrion (hepatic): proximal urea-cycle steps (NAGS, CPS1, OTC) and ammonia delivery to mitochondria; mitochondrial locus of key failures in proximal UCDs (chanvanichtrakool2024unravelingthelink pages 9-12, duff2024genetherapyfor pages 2-4).
Cytosol (hepatocyte): distal urea-cycle steps (ASS1, ASL, ARG1) (chanvanichtrakool2024unravelingthelink pages 9-12).
Astrocyte cytosol and mitochondria: glutamine synthesis and ammonia-related mitochondrial dysfunction/oxidative stress (enokizono2023neuroimagingfindingsof pages 4-6, lu2023cellularpathogenesisof pages 2-4).
Blood–brain barrier (BBB): ammonia entry route; neurovascular involvement recognized in hyperammonemia states (enokizono2023neuroimagingfindingsof pages 4-6, lu2023cellularpathogenesisof pages 2-4).

5. Disease progression model (sequence of events)

Stage 0: genetic defect and reduced urea-cycle flux

Inherited deficiency in a urea-cycle enzyme/transporter reduces hepatic ureagenesis capacity (yin2024asurvivalguide pages 16-19).

Stage 1: trigger-driven catabolic stress

Infections, fasting, postpartum or postoperative stress, increased protein intake, and medications such as valproate can precipitate hyperammonemia in susceptible individuals, including partial/late-onset forms (meier2024noncirrhotichyperammonemiaand pages 13-16, nteli2024argininemiapathophysiologyand pages 2-3).

Stage 2: hyperammonemia and systemic metabolic derangements

Rising ammonia and related amino-acid derangements (low citrulline/arginine; high glutamine; orotic acid in OTC) emerge; compensation via glutamine synthesis can be overwhelmed (fenves2025gastricbypassassociated pages 10-12, meier2024noncirrhotichyperammonemiaand pages 13-16).

Stage 3: brain ammonia influx → astrocyte glutamine accumulation → edema and network dysfunction

Ammonia crosses BBB and is converted to glutamine; glutamine acts as osmolyte producing astrocyte swelling and cerebral edema. Neurotransmission and energy metabolism are perturbed, facilitating seizures/encephalopathy (chanvanichtrakool2024unravelingthelink pages 1-3, enokizono2023neuroimagingfindingsof pages 4-6).

Stage 4: clinical manifestations and outcomes

Clinical spectrum ranges from neonatal rapidly progressive encephalopathy/coma to recurrent late-onset episodes. In some UCDs (e.g., ARG1 deficiency), progressive spasticity dominates; in others, severe crises cause death or neurologic sequelae (yin2024asurvivalguide pages 16-19, nteli2024argininemiapathophysiologyand pages 2-3).

6. Phenotypic manifestations (HP-oriented) and mechanistic links

Representative phenotypes explicitly noted across retrieved sources: - Hyperammonemic encephalopathy / altered mental status / coma (ammonia neurotoxicity; edema) (yin2024asurvivalguide pages 16-19). - Seizures (including subclinical seizures): linked to severity of hyperammonemia and glutamine; mechanisms include excitotoxicity, AQP4 changes, energy metabolism disruption, NO impairment (chanvanichtrakool2024unravelingthelink pages 1-3). - Cerebral edema: glutamine osmotic effect and astrocyte swelling (chanvanichtrakool2024unravelingthelink pages 1-3, enokizono2023neuroimagingfindingsof pages 4-6). - Developmental delay / intellectual disability / motor impairment: prominent in specific subtypes (ASLD developmental delay/epilepsy; ARG1 spastic diplegia) (duff2024genetherapyfor pages 2-4, nteli2024argininemiapathophysiologyand pages 2-3). - Liver disease (hepatomegaly/fibrosis/chronic liver disease): noted in UCDs and mechanistically emphasized in ASL deficiency via glutathione dysregulation (gurung2024mrnatherapycorrects pages 1-3, duff2024genetherapyfor pages 2-4).

7. Recent developments (prioritizing 2023–2024)

7.1 Quantitative seizure risk modeling during UCD crises (2024)

In a UCD cohort study (Pediatric Neurology, Oct 2024; https://doi.org/10.1016/j.pediatrneurol.2024.06.013), seizures occurred in 13% of hyperammonemic events, while EEG revealed frequent occult seizures (subclinical seizures in 27% of encephalopathic crises without clinical seizures; 53% when clinical seizures were present). Biochemically, seizure odds increased 2.65-fold per 100 µmol/L ammonia and 1.14-fold per 100 µmol/L glutamine, supporting combined ammonia+glutamine risk stratification and neuromonitoring decisions (chanvanichtrakool2024unravelingthelink pages 1-3).

7.2 Neuroimaging biomarkers of hyperammonemic injury (2023)

A 2023 radiology review emphasizes ^1H-MRS patterns in UCDs: elevated lactate and Glx, and reduced myo-inositol (osmolyte buffer) correlating with severity, consistent with glutamine-driven osmotic stress biology (Enokizono et al., Feb 2023; https://doi.org/10.1007/s11604-023-01396-0) (enokizono2023neuroimagingfindingsof pages 4-6).

7.3 ASL deficiency: glutathione metabolism + PET biomarker + mRNA therapy (2024)

Gurung et al. (Science Translational Medicine, Jan 2024; https://doi.org/10.1126/scitranslmed.adh1334) provide mechanistic evidence that ASL deficiency includes a liver redox/glutathione defect and propose [18F]FSPG PET to monitor disease and response (gurung2024mrnatherapycorrects pages 1-3). Quantitatively, [18F]FSPG retention decreased from 22 ± 2.3 %ID/g (untreated) to 11 ± 2.0 %ID/g (mRNA-treated) (p=0.026), compared to 5.0 ± 2.8 %ID/g in wild-type; ureagenesis was restored (stable isotope labeling), and hepatic glutathione was restored to near WT (gurung2024mrnatherapycorrects pages 7-9).

7.4 Gene and RNA therapeutics: delivery constraints and design principles (2024)

A 2024 gene-therapy review highlights that small increases in residual enzyme activity can produce substantial clinical benefit and cites a functional threshold around ~10% activity, but notes that required hepatocyte coverage may be higher; it also emphasizes liver zonation (periportal enzyme enrichment) and the challenge of episomal-vector dilution in growing pediatric livers (Duff et al., Apr 2024; https://doi.org/10.1002/jimd.12609) (duff2024genetherapyfor pages 2-4). A 2024 RNA-therapeutics review describes hepatocyte-targeted delivery platforms (LNPs, GalNAc conjugates) and notes that mRNA approaches are transient (necessitating re-dosing) while gene editing offers “potential… permanent correction… after a single dose,” albeit with safety risks and delivery limitations (Richard et al., Oct 2024; https://doi.org/10.1002/jimd.12807) (richard2024exploringrnatherapeutics pages 1-2, richard2024exploringrnatherapeutics pages 6-7).

8. Current applications and real-world implementation

8.1 Acute hyperammonemia management thresholds and dialysis triggers

A clinical “survival guide” for UCD crises provides operational thresholds: in neonates, suspect IEM at >200 µmol/L; after neonatal period, suspect IEM at >100 µmol/L. Very poor prognosis is associated with plasma NH4+ >1000 µmol/L and prolonged coma; extracorporeal therapy is recommended when ammonia escalates to >500 µmol/L or if encephalopathic, specifying CRRT initiation (yin2024asurvivalguide pages 16-19).

8.2 Nitrogen scavengers (mechanism, dosing, monitoring)

Sodium phenylbutyrate is a nitrogen-binding agent for chronic UCD management (selected enzyme deficiencies) and is “metabolized to phenylacetate,” which “conjugates with glutamine… to form phenylacetylglutamine,” excreted by kidneys—an alternative route for waste nitrogen excretion (mechanism-of-action section) (burlina2023longtermmanagementof pages 5-8). Dosing and monitoring include weight/BSA-based daily dosing (max 20 g/day), plasma ammonia monitoring for dose adjustment, and vigilance for phenylacetate-associated neurotoxicity and hypokalemia due to phenylacetylglutamine renal loss (burlina2023longtermmanagementof pages 1-2).

8.3 Urea-cycle intermediate supplementation: citrulline vs arginine (quantitative clinical data)

A large retrospective cohort (Orphanet J Rare Dis, Jul 2023; https://doi.org/10.1186/s13023-023-02800-8) reported mean ammonia concentrations during supplementation periods of 35.9 µmol/L with citrulline, 49.8 µmol/L with arginine, and 53.0 µmol/L with arginine+citrulline; citrulline increased plasma arginine from 67.6 to 84.9 µmol/L (P<0.05) (imbard2023citrullineinthe pages 1-2). Mechanistically, citrulline “is converted to arginine through the renal pathway of arginine synthesis,” and unlike arginine, citrulline does not undergo extensive intestinal/hepatic metabolism, improving arginine bioavailability (imbard2023citrullineinthe pages 10-11).

8.4 Liver transplantation and long-term follow-up

Expert gene-therapy and bibliometric syntheses emphasize that liver transplantation is currently the only curative option for many UCDs, but carries morbidity and life-long immunosuppression, motivating gene/RNA therapy development (duff2024genetherapyfor pages 1-2, wang2025globalresearchdynamics pages 1-2).

9. Expert opinion and analysis (authoritative sources)

Liver-targeting rationale: Because urea-cycle enzymes are expressed in liver (periportal hepatocytes) and the liver has favorable delivery anatomy (high blood flow and fenestrated endothelium), hepatocyte-directed gene/RNA therapies are prioritized; however, zonation and the need for broad periportal correction complicate delivery optimization (Duff et al., Apr 2024; https://doi.org/10.1002/jimd.12609) (duff2024genetherapyfor pages 2-4).
Evidence gaps: Clinical trials are difficult because UCDs are rare and high-level evidence for many management decisions is limited; thus, expert consensus and real-world cohort analyses remain central to practice (framed in expert-opinion literature around mild UCDs and newborn screening, and reflected by reliance on retrospective data for supplementation comparisons) (duff2024genetherapyfor pages 1-2, imbard2023citrullineinthe pages 1-2).

10. Statistics and data highlights (recent)

Epidemiology

Incidence estimate: UCD incidence ~1 in 35,000 births (North America; cited in 2024 cohort study) (chanvanichtrakool2024unravelingthelink pages 1-3).

Crisis severity thresholds (practice guidance)

Neonate: “Healthy <110 µmol/L”; “Suspect IEM >200 µmol/L.” Post-neonatal: “Healthy <50 µmol/L”; “Suspect IEM >100 µmol/L.” Dialysis/CRRT trigger: >500 µmol/L or encephalopathy; poor prognosis at >1000 µmol/L (yin2024asurvivalguide pages 16-19).

Seizure risk quantification (2024)

Seizures in 13% of HA events; odds ratio 2.65 per 100 µmol/L ammonia and 1.14 per 100 µmol/L glutamine; subclinical seizure detection rates 27% and 53% depending on clinical seizure status (chanvanichtrakool2024unravelingthelink pages 1-3).

Supplementation outcomes (2023)

Mean ammonia: citrulline 35.9 µmol/L, arginine 49.8 µmol/L, combo 53.0 µmol/L (imbard2023citrullineinthe pages 1-2).

ASA/ASLD biomarker and treatment response (2024)

[18F]FSPG PET retention: 22 ± 2.3 %ID/g untreated vs 11 ± 2.0 %ID/g treated vs 5.0 ± 2.8 %ID/g WT (gurung2024mrnatherapycorrects pages 7-9).

11. Knowledge-base annotation section (ontology-oriented)

11.1 Gene/protein annotations (HGNC-style)

NAGS, CPS1, OTC, ASS1, ASL, ARG1, SLC25A15, SLC25A13 — causal for major UCD subtypes (yin2024asurvivalguide pages 16-19).

11.2 Cell type involvement (CL-style)

Hepatocyte (periportal hepatocyte) — primary disease cell type for ureagenesis failure and main therapeutic target (yin2024asurvivalguide pages 16-19, duff2024genetherapyfor pages 2-4).
Astrocyte — central mediator of brain ammonia detoxification, glutamine accumulation, swelling/edema and neurotoxicity (enokizono2023neuroimagingfindingsof pages 4-6, lu2023cellularpathogenesisof pages 2-4).

11.3 Anatomical locations (UBERON-style)

Liver (periportal zones) — urea-cycle enzyme expression and ureagenesis (yin2024asurvivalguide pages 16-19, duff2024genetherapyfor pages 2-4).
Brain / blood–brain barrier — ammonia diffusion and astrocyte response; MRS biomarkers (enokizono2023neuroimagingfindingsof pages 4-6).

11.4 Chemicals (CHEBI-style; representative)

Ammonia, glutamine, citrulline, arginine, orotic acid (key biomarkers/effectors) (fenves2025gastricbypassassociated pages 10-12, enokizono2023neuroimagingfindingsof pages 4-6, imbard2023citrullineinthe pages 1-2).
Sodium phenylbutyrate / phenylacetate / phenylacetylglutamine (nitrogen-scavenging axis) (burlina2023longtermmanagementof pages 5-8).
Sodium benzoate (nitrogen scavenger) (yin2024asurvivalguide pages 16-19).
[18F]FSPG PET radiotracer (ASA biomarker) (gurung2024mrnatherapycorrects pages 1-3).

11.5 Disrupted biological processes (GO-style)

Urea cycle/ammonia detoxification (yin2024asurvivalguide pages 16-19)
Astrocyte glutamine synthesis and osmotic swelling/cerebral edema (enokizono2023neuroimagingfindingsof pages 4-6)
Neurotransmission regulation/excitotoxicity; energy metabolism disruption (chanvanichtrakool2024unravelingthelink pages 1-3)
Glutathione metabolism/antioxidant pathways in ASL deficiency (gurung2024mrnatherapycorrects pages 1-3)

11.6 Phenotype associations (HP-style; representative)

Hyperammonemia; encephalopathy/coma; seizures; cerebral edema; developmental delay; spastic diplegia/paraparesis; liver fibrosis/cirrhosis (yin2024asurvivalguide pages 16-19, nteli2024argininemiapathophysiologyand pages 2-3, chanvanichtrakool2024unravelingthelink pages 1-3).

12. Evidence items (with URLs and publication dates; PMIDs where available)

Note on PMIDs: The retrieved excerpts predominantly include DOIs/URLs but not PubMed IDs; therefore, PMID-level citation could not be consistently provided from available context.

Enokizono M. et al. Japanese Journal of Radiology — “Neuroimaging findings of inborn errors of metabolism: urea cycle disorders…” (Feb 2023). https://doi.org/10.1007/s11604-023-01396-0 (enokizono2023neuroimagingfindingsof pages 4-6)
Lu K. Biomolecules — “Cellular Pathogenesis of Hepatic Encephalopathy: An Update” (Feb 2023). https://doi.org/10.3390/biom13020396 (lu2023cellularpathogenesisof pages 1-2, lu2023cellularpathogenesisof pages 2-4)
Imbard A. et al. Orphanet Journal of Rare Diseases — “Citrulline in the management of patients with urea cycle disorders” (Jul 2023). https://doi.org/10.1186/s13023-023-02800-8 (imbard2023citrullineinthe pages 1-2)
Duff C. et al. Journal of Inherited Metabolic Disease — “Gene therapy for urea cycle defects…” (Apr 2024). https://doi.org/10.1002/jimd.12609 (duff2024genetherapyfor pages 1-2, duff2024genetherapyfor pages 2-4)
Richard E. et al. Journal of Inherited Metabolic Disease — “Exploring RNA therapeutics for urea cycle disorders” (Oct 2024). https://doi.org/10.1002/jimd.12807 (richard2024exploringrnatherapeutics pages 1-2, richard2024exploringrnatherapeutics pages 6-7)
Chanvanichtrakool M. et al. Pediatric Neurology — “Unraveling the Link: Seizure Characteristics and Ammonia Levels in Urea Cycle Disorder During Hyperammonemic Crises” (Oct 2024). https://doi.org/10.1016/j.pediatrneurol.2024.06.013 (chanvanichtrakool2024unravelingthelink pages 1-3)
Gurung S. et al. Science Translational Medicine — “mRNA therapy corrects defective glutathione metabolism and restores ureagenesis…” (Jan 2024). https://doi.org/10.1126/scitranslmed.adh1334 (gurung2024mrnatherapycorrects pages 7-9, gurung2024mrnatherapycorrects pages 1-3)
PHEBURANE (sodium phenylbutyrate) FDA label (Revised Jun 2022) — mechanism: phenylacetate conjugates with glutamine to phenylacetylglutamine; clinical dosing and monitoring (burlina2023longtermmanagementof pages 5-8, burlina2023longtermmanagementof pages 1-2)

Limitations of this synthesis

MONDO ID and PMIDs were not provided in the retrieved excerpts, though DOIs/URLs and publication dates are included.
Some mechanistic details (e.g., oxidative/nitrosative stress pathways and BBB inflammation) are best characterized in broader hyperammonemia literature; UCD-specific texts here emphasize osmotic glutamine mechanisms, excitotoxicity, energy metabolism disruption, and nitric oxide impairment, with more detailed oxidative stress mechanisms implied via related reviews (lu2023cellularpathogenesisof pages 2-4).

References

(yin2024asurvivalguide pages 16-19): LH YIN. A survival guide a survival guide. Unknown journal, 2024.
(duff2024genetherapyfor pages 1-2): Claire Duff, Ian E. Alexander, and Julien Baruteau. Gene therapy for urea cycle defects: an update from historical perspectives to future prospects. Journal of Inherited Metabolic Disease, 47:50-62, Apr 2024. URL: https://doi.org/10.1002/jimd.12609, doi:10.1002/jimd.12609. This article has 27 citations and is from a peer-reviewed journal.
(fenves2025gastricbypassassociated pages 12-15): Andrew Z. Fenves, Dilara Hatipoglu, John C. Robinson, and Michael M. Rothkopf. Gastric bypass associated hyperammonemia (gabha): a case study, scoping review of the literature, and proposed new pathophysiologic mechanism. Metabolites, 15:573, Aug 2025. URL: https://doi.org/10.3390/metabo15090573, doi:10.3390/metabo15090573. This article has 0 citations.
(fenves2025gastricbypassassociated pages 10-12): Andrew Z. Fenves, Dilara Hatipoglu, John C. Robinson, and Michael M. Rothkopf. Gastric bypass associated hyperammonemia (gabha): a case study, scoping review of the literature, and proposed new pathophysiologic mechanism. Metabolites, 15:573, Aug 2025. URL: https://doi.org/10.3390/metabo15090573, doi:10.3390/metabo15090573. This article has 0 citations.
(erdal2025aminoacidmetabolism pages 4-4): Ranya Erdal, Kıvanç Birsoy, and Gokhan Unlu. Amino acid metabolism in liver mitochondria: from homeostasis to disease. Metabolites, 15:446, Jul 2025. URL: https://doi.org/10.3390/metabo15070446, doi:10.3390/metabo15070446. This article has 1 citations.
(nteli2024argininemiapathophysiologyand pages 2-3): Despoina Nteli, Maria Nteli, Konstantinos Konstantinidis, Anastasia Foka, Foteini Charisi, Iliana Michailidou, Sotiria Stavropoulou De Lorenzo, Marina Boziki, Maria Tzitiridou-Chatzopoulou, Evangelia Spandou, Constantina Simeonidou, Christos Bakirtzis, and Evangelia Kesidou. Argininemia: pathophysiology and novel methods for evaluation of the disease. Applied Sciences, 14:1647, Feb 2024. URL: https://doi.org/10.3390/app14041647, doi:10.3390/app14041647. This article has 3 citations.
(enokizono2023neuroimagingfindingsof pages 4-6): Mikako Enokizono, Noriko Aida, Akira Yagishita, Yasuhiro Nakata, Reiko Ideguchi, Ryo Kurokawa, Tatsuo Kono, Toshio Moritani, and Harushi Mori. Neuroimaging findings of inborn errors of metabolism: urea cycle disorders, aminoacidopathies, and organic acidopathies. Japanese Journal of Radiology, 41:683-702, Feb 2023. URL: https://doi.org/10.1007/s11604-023-01396-0, doi:10.1007/s11604-023-01396-0. This article has 11 citations and is from a peer-reviewed journal.
(chanvanichtrakool2024unravelingthelink pages 1-3): Mongkol Chanvanichtrakool, John M. Schreiber, Wei-Liang Chen, John Barber, Anqing Zhang, Nicholas Ah Mew, Andreas Schulze, Greta Wilkening, Sandesh C.S. Nagamani, and Andrea Gropman. Unraveling the link: seizure characteristics and ammonia levels in urea cycle disorder during hyperammonemic crises. Pediatric Neurology, 159:48-55, Oct 2024. URL: https://doi.org/10.1016/j.pediatrneurol.2024.06.013, doi:10.1016/j.pediatrneurol.2024.06.013. This article has 3 citations and is from a peer-reviewed journal.
(lu2023cellularpathogenesisof pages 1-2): Kaihui Lu. Cellular pathogenesis of hepatic encephalopathy: an update. Biomolecules, 13:396, Feb 2023. URL: https://doi.org/10.3390/biom13020396, doi:10.3390/biom13020396. This article has 63 citations.
(lu2023cellularpathogenesisof pages 2-4): Kaihui Lu. Cellular pathogenesis of hepatic encephalopathy: an update. Biomolecules, 13:396, Feb 2023. URL: https://doi.org/10.3390/biom13020396, doi:10.3390/biom13020396. This article has 63 citations.
(duff2024genetherapyfor pages 2-4): Claire Duff, Ian E. Alexander, and Julien Baruteau. Gene therapy for urea cycle defects: an update from historical perspectives to future prospects. Journal of Inherited Metabolic Disease, 47:50-62, Apr 2024. URL: https://doi.org/10.1002/jimd.12609, doi:10.1002/jimd.12609. This article has 27 citations and is from a peer-reviewed journal.
(gurung2024mrnatherapycorrects pages 1-3): Sonam Gurung, Oskar Vilhelmsson Timmermand, Dany Perocheau, Ana Luisa Gil-Martinez, Magdalena Minnion, Loukia Touramanidou, Sherry Fang, Martina Messina, Youssef Khalil, Justyna Spiewak, Abigail R. Barber, Richard S. Edwards, Patricia Lipari Pinto, Patrick F. Finn, Alex Cavedon, Summar Siddiqui, Lisa Rice, Paolo G. V. Martini, Deborah Ridout, Wendy Heywood, Ian Hargreaves, Simon Heales, Philippa B. Mills, Simon N. Waddington, Paul Gissen, Simon Eaton, Mina Ryten, Martin Feelisch, Andrea Frassetto, Timothy H. Witney, and Julien Baruteau. Mrna therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria. Science translational medicine, 16:eadh1334-eadh1334, Jan 2024. URL: https://doi.org/10.1126/scitranslmed.adh1334, doi:10.1126/scitranslmed.adh1334. This article has 31 citations and is from a highest quality peer-reviewed journal.
(meier2024noncirrhotichyperammonemiaand pages 13-16): Ciselle Ayumi Meier. Non-cirrhotic hyperammonemia and adult-onset metabolic disorders: under-recognised presentation among emergency clinicians. Other, 2024. URL: https://doi.org/10.26182/fbbe-3162, doi:10.26182/fbbe-3162. This article has 0 citations.
(imbard2023citrullineinthe pages 1-2): Apolline Imbard, Juliette Bouchereau, Jean-Baptiste Arnoux, Anaïs Brassier, Manuel Schiff, Claire-Marine Bérat, Clément Pontoizeau, Jean-François Benoist, Constant Josse, François Montestruc, and Pascale de Lonlay. Citrulline in the management of patients with urea cycle disorders. Orphanet Journal of Rare Diseases, Jul 2023. URL: https://doi.org/10.1186/s13023-023-02800-8, doi:10.1186/s13023-023-02800-8. This article has 14 citations and is from a peer-reviewed journal.
(imbard2023citrullineinthe pages 10-11): Apolline Imbard, Juliette Bouchereau, Jean-Baptiste Arnoux, Anaïs Brassier, Manuel Schiff, Claire-Marine Bérat, Clément Pontoizeau, Jean-François Benoist, Constant Josse, François Montestruc, and Pascale de Lonlay. Citrulline in the management of patients with urea cycle disorders. Orphanet Journal of Rare Diseases, Jul 2023. URL: https://doi.org/10.1186/s13023-023-02800-8, doi:10.1186/s13023-023-02800-8. This article has 14 citations and is from a peer-reviewed journal.
(burlina2023longtermmanagementof pages 5-8): Alberto Burlina, Serena Gasperini, Giancarlo la Marca, Andrea Pession, Barbara Siri, Marco Spada, Margherita Ruoppolo, and Albina Tummolo. Long-term management of patients with mild urea cycle disorders identified through the newborn screening: an expert opinion for clinical practice. Nutrients, 16:13, Dec 2023. URL: https://doi.org/10.3390/nu16010013, doi:10.3390/nu16010013. This article has 10 citations.
(gurung2024mrnatherapycorrects pages 3-4): Sonam Gurung, Oskar Vilhelmsson Timmermand, Dany Perocheau, Ana Luisa Gil-Martinez, Magdalena Minnion, Loukia Touramanidou, Sherry Fang, Martina Messina, Youssef Khalil, Justyna Spiewak, Abigail R. Barber, Richard S. Edwards, Patricia Lipari Pinto, Patrick F. Finn, Alex Cavedon, Summar Siddiqui, Lisa Rice, Paolo G. V. Martini, Deborah Ridout, Wendy Heywood, Ian Hargreaves, Simon Heales, Philippa B. Mills, Simon N. Waddington, Paul Gissen, Simon Eaton, Mina Ryten, Martin Feelisch, Andrea Frassetto, Timothy H. Witney, and Julien Baruteau. Mrna therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria. Science translational medicine, 16:eadh1334-eadh1334, Jan 2024. URL: https://doi.org/10.1126/scitranslmed.adh1334, doi:10.1126/scitranslmed.adh1334. This article has 31 citations and is from a highest quality peer-reviewed journal.
(gurung2024mrnatherapycorrects pages 7-9): Sonam Gurung, Oskar Vilhelmsson Timmermand, Dany Perocheau, Ana Luisa Gil-Martinez, Magdalena Minnion, Loukia Touramanidou, Sherry Fang, Martina Messina, Youssef Khalil, Justyna Spiewak, Abigail R. Barber, Richard S. Edwards, Patricia Lipari Pinto, Patrick F. Finn, Alex Cavedon, Summar Siddiqui, Lisa Rice, Paolo G. V. Martini, Deborah Ridout, Wendy Heywood, Ian Hargreaves, Simon Heales, Philippa B. Mills, Simon N. Waddington, Paul Gissen, Simon Eaton, Mina Ryten, Martin Feelisch, Andrea Frassetto, Timothy H. Witney, and Julien Baruteau. Mrna therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria. Science translational medicine, 16:eadh1334-eadh1334, Jan 2024. URL: https://doi.org/10.1126/scitranslmed.adh1334, doi:10.1126/scitranslmed.adh1334. This article has 31 citations and is from a highest quality peer-reviewed journal.
(chanvanichtrakool2024unravelingthelink pages 9-12): Mongkol Chanvanichtrakool, John M. Schreiber, Wei-Liang Chen, John Barber, Anqing Zhang, Nicholas Ah Mew, Andreas Schulze, Greta Wilkening, Sandesh C.S. Nagamani, and Andrea Gropman. Unraveling the link: seizure characteristics and ammonia levels in urea cycle disorder during hyperammonemic crises. Pediatric Neurology, 159:48-55, Oct 2024. URL: https://doi.org/10.1016/j.pediatrneurol.2024.06.013, doi:10.1016/j.pediatrneurol.2024.06.013. This article has 3 citations and is from a peer-reviewed journal.
(richard2024exploringrnatherapeutics pages 1-2): Eva Richard, Ainhoa Martínez‐Pizarro, and Lourdes R. Desviat. Exploring rna therapeutics for urea cycle disorders. Journal of Inherited Metabolic Disease, 47:1269-1277, Oct 2024. URL: https://doi.org/10.1002/jimd.12807, doi:10.1002/jimd.12807. This article has 4 citations and is from a peer-reviewed journal.
(richard2024exploringrnatherapeutics pages 6-7): Eva Richard, Ainhoa Martínez‐Pizarro, and Lourdes R. Desviat. Exploring rna therapeutics for urea cycle disorders. Journal of Inherited Metabolic Disease, 47:1269-1277, Oct 2024. URL: https://doi.org/10.1002/jimd.12807, doi:10.1002/jimd.12807. This article has 4 citations and is from a peer-reviewed journal.
(burlina2023longtermmanagementof pages 1-2): Alberto Burlina, Serena Gasperini, Giancarlo la Marca, Andrea Pession, Barbara Siri, Marco Spada, Margherita Ruoppolo, and Albina Tummolo. Long-term management of patients with mild urea cycle disorders identified through the newborn screening: an expert opinion for clinical practice. Nutrients, 16:13, Dec 2023. URL: https://doi.org/10.3390/nu16010013, doi:10.3390/nu16010013. This article has 10 citations.
(wang2025globalresearchdynamics pages 1-2): Yan Wang, Xueer Wang, Huiqin Zhang, and Binhui Zhu. Global research dynamics in urea cycle disorders: a bibliometric study highlighting key players and future directions. Orphanet Journal of Rare Diseases, Mar 2025. URL: https://doi.org/10.1186/s13023-025-03625-3, doi:10.1186/s13023-025-03625-3. This article has 2 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Source YAML

References & Deep Research

References

Deep Research

Disorder

Key Pathophysiology Nodes

Citation Inventory (for evidence mapping)

Disease Pathophysiology Research Template

Target Disease

Research Objectives

Required Information

1. Core Pathophysiology

2. Key Molecular Players

3. Biological Processes (for GO annotation)

4. Cellular Components

5. Disease Progression

6. Phenotypic Manifestations

Citation Requirements

Output Format

Pathophysiology Research Report — Urea Cycle Disorders (UCDs) (Genetic)

Scope and disease definition

1. Core pathophysiology (molecular/cellular mechanisms)

1.1 Primary mechanism: failure of hepatic ureagenesis → hyperammonemia

1.2 Brain pathophysiology of hyperammonemia (central mechanism of morbidity)

1.3 Liver pathophysiology beyond ammonia: oxidative stress/redox and chronic liver disease (ASL deficiency exemplar)

2. Key molecular players

2.1 Genes/proteins (causal)

2.2 Chemical entities / metabolites

2.3 Cell types (primary)

2.4 Anatomical locations

3. Dysregulated pathways and biological processes (GO-oriented)

3.1 Biological processes

3.2 Dysregulated molecular pathways (conceptual)

4. Cellular components (GO-CC oriented)

5. Disease progression model (sequence of events)

Stage 0: genetic defect and reduced urea-cycle flux

Stage 1: trigger-driven catabolic stress

Stage 2: hyperammonemia and systemic metabolic derangements

Stage 3: brain ammonia influx → astrocyte glutamine accumulation → edema and network dysfunction

Stage 4: clinical manifestations and outcomes

6. Phenotypic manifestations (HP-oriented) and mechanistic links

7. Recent developments (prioritizing 2023–2024)

7.1 Quantitative seizure risk modeling during UCD crises (2024)

7.2 Neuroimaging biomarkers of hyperammonemic injury (2023)

7.3 ASL deficiency: glutathione metabolism + PET biomarker + mRNA therapy (2024)

7.4 Gene and RNA therapeutics: delivery constraints and design principles (2024)

8. Current applications and real-world implementation

8.1 Acute hyperammonemia management thresholds and dialysis triggers

8.2 Nitrogen scavengers (mechanism, dosing, monitoring)

8.3 Urea-cycle intermediate supplementation: citrulline vs arginine (quantitative clinical data)

8.4 Liver transplantation and long-term follow-up

9. Expert opinion and analysis (authoritative sources)

10. Statistics and data highlights (recent)

Epidemiology

Crisis severity thresholds (practice guidance)

Seizure risk quantification (2024)

Supplementation outcomes (2023)

ASA/ASLD biomarker and treatment response (2024)

11. Knowledge-base annotation section (ontology-oriented)

11.1 Gene/protein annotations (HGNC-style)

11.2 Cell type involvement (CL-style)

11.3 Anatomical locations (UBERON-style)

11.4 Chemicals (CHEBI-style; representative)

11.5 Disrupted biological processes (GO-style)

11.6 Phenotype associations (HP-style; representative)

12. Evidence items (with URLs and publication dates; PMIDs where available)

Limitations of this synthesis